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Abstract 
 Cardiovascular disease kills nearly 1 million Americans each year. While 
treatment at all levels has made significant advances over the past 3 decades, 
diagnosis is still limited to structural or hemodynamic changes associated with 
advanced disease. More than 60% of myocardial infarctions (MI) result from the 
rupture and associated acute thrombosis of atherosclerotic plaque that reduce 
lumen size by less that 50%. Ultra small superparamagnetic iron oxide particles 
(USPIO) have recently been proposed as a macrophage targeted magnetic 
resonance contrast agent. The goal of the present study was to determine if, and 
the extent to which, molecules known to alter macrophage metabolism 
significantly alter the extent to which USPIO’s are internalized in these cells. 
 
Murine macrophage cells (J774) known to be constitutively activated, were 
cultured in 8 well chamber slides. One group of 4 wells was treated for 24 hours 
with the test agent. Control and treated cells were then incubated for 4 hours with 
0.0µL, 1.0 µL (11.2 µg Fe), 10.0 µL (112.0 µg Fe) and 100.0 µL (1.12 mg Fe) of 
stock USPIO (Feridex, Berlex labs). Cell density and iron uptake was quantified 
using spectral analysis of digital microscope images of fixed cells stained with 
acridine orange and counterstained with Prussian Blue.  
 
Macrophage uptake of USPIO was significantly related to iron concentration (r2= 
0.992). However there was saturation of cell uptake at higher USPIO 
concentration. Uptake, (iron area/total image area) expressed as the percent, 
became significantly greater than background by 5 minutes (0.084+ 0.001% 
versus 0.045 +0.029%, p=0.028) and peaked at 4 hours. At low dose (10 and 20 
ng/ml) Interleukin-4 did not affect cell uptake of USPIO. However at 40 ng/ml, IL-
4 produced a significant increase in iron endocytosis at 1.12 mg Fe/ml (2-way 
ANOVA, p=0.032). Similarly, Human Interferon gamma (IFN-γ) had no effect at 
the 3 lower doses (10, 100, and 500 International Units (IU)/ml, corresponding to 
0.5, 5.0, 25.0 and 50 ng/ml). Treatment with 1000 IU/ml resulted in an increase in 
cell uptake (2-way ANOVA, p=0.045). 
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 To test the importance of serum proteins on endocytosis, a group of cells were 
cultured with and without 10% fetal bovine serum (FBS). Absence of FBS 
resulted in a substantial reduction in USPIO uptake (p<0.001). There was also a 
trend toward reduced cell density compared to control (p=0.056) which is likely 
the effect of the absence of growth factors in the FBS free cell cultures. 
 
Cytochalsin-B depolarizes actin filaments within macrophage plasma membrane 
and thus inhibits membrane invagination and thus endocytosis. At a dose of 1.0 
µg/ml  it has been previously been shown to preferentially inhibit endocytosis of 
larger particles (> 300 nm) with little effect on small (< 300 nm). In the present 
study, USPIO uptake trended toward being reduced (p=0.062) indicating that 
although individual particle size was small (100-150 nm), the aggregation of 
these particles results in a larger effective size in terms of trans-membrane 
pathway.  
 
The test USPIO was coated with a thin layer of dextran-10. The mannose 
receptor has broad affinity to polysaccharide moieties. To test the potential for 
this receptor to be involved in USPIO endocytosis the receptor was blocked with 
mannan. There was no significant inhibition of endocytosis (p=0.188) excluding 
this receptor as a major endocytotic pathway for the tested USPIO. 
 
Both angiotensin converting enzyme inhibiting drugs and HMG-CoA reductase 
inhibiting medications are used widely for control of hypertension and lipid 
lowering therapy respectively. Cells were treated with Captopril at doses of 
0.001, 0.01, 0.1 and 1.0mM. Even at the highest dose there was no difference 
between treated and control cells in terns of cell density or USPIO uptake. 
Treatment with the statin mevinolin resulted substantial inhibition of USPIO 
uptake at 1.0 and 17.5 µM (p=0.004 and p<0.001 respectively). In addition cell 
density was reduced at the higher dose compared to control (p=0.033) which is in 
agreement with this agents known macrophage anti-proliferative properties. 
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 This study suggests that USPIO’s enter macrophages via a number of different 
pathways including opsonification to serum proteins, scavenger receptors and 
fluid phase endocytosis. The effect of the actin blocking agent cytochalasin-B 
indicates that the size of USPIO aggregates rather than individual particles 
determine the rate of endocytosis.  
 
Finally, these data provide evidence that substantial regulation of USPIO uptake 
occurs by both endogenous (cytokines) and exogenous agents (HMG Co-A 
reductase inhibitors). Mevinolin therapy may reduce the sensitivity for USPIO 
agents to detect the presence of macrophages in the vessel wall. Although it is 
beyond the scope of this study, it would be of interest to determine if mevinolin 
treated macrophages recover endocytotic capacity after treatment is withdrawn 
or whether the effect is permanent.   If USPIO enhanced MRI can detect 
macrophage loss of function, and if this effect is related to inflammation or plaque 
stability, MRI could have a role in determining the effectiveness of statin as well 
as other drug therapies aimed at treating atherosclerotic disease. 
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Introduction 
 
 
Macrophages as Markers of Atherosclerosis 
Until recently atherosclerosis was considered a bland lipid storage disease. Data 
from basic research, pathologic analysis and clinical epidemiological studies 
have shown that atherosclerosis is intrinsically an inflammatory disease1,2.  As 
such, the initiation and progression of this disease are controlled by immune 
response mechanisms3 In general, inflammation is a defense reaction caused by 
tissue damage, or infection, characterized by redness, heat, swelling, and pain. 
The primary objective of inflammation is to localize and eradicate the irritant and 
repair the surrounding tissue. For the survival of the host, inflammation is a 
necessary and beneficial process. The inflammatory response involves three 
major stages: first, dilation of capillaries to increase blood flow; second, 
microvascular structural changes and escape of plasma proteins from the 
bloodstream; and third, leukocyte transmigration through endothelium and 
accumulation at the site of injury. It 
is this normal response to injury 
which initiates the atherosclerotic 
cascade within the vessel wall. 
Normal vascular endothelium does 
not support binding of leukocytes 
(including monocytes). However 
regardless of the form of “injury 
(hyperlipidemia4, hypertension5 , 
even low laminar sheer stress6) 
endothelial cells begin to express 
adhesion molecules, such as 
vascular cell adhesion molecule-1 (VCAM-1) that bind to various classes of 
leukocytes initiating the capture of monocytes and T-lymphocytes as shown in 
figure 17 Once attached to the endothelium, leukocytes migrate across 
Figure 1: Cartoon illustrating leukocyte 
adhesion and endothelial transmigration. 
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endothelium if an exogenous chemo-attractant is present within the intima. 
Chemoattractant cytokines or chemokines are small disulphide-linked 
polypeptides, typically of 60–70 amino acids in length, and are potent 
chemoattractants for leukocytes such as T cells, natural killer (NK) cells, 
monocytes and macrophages.8 Monocyte chemo-attractant protein-1 (MCP-1) is 
one member of this family9. Chemokines mediate their effects via interaction with 
specific chemokine receptors expressed on a wide range of cell types. Binding of 
a chemokine to its specific receptor on the cell surface leads to the generation of 
an intracellular signal via a GαI-containing G-protein complex and this results in 
cell chemotaxis towards the source of the chemokine. Thus the entry of 
monocytes into the vessel wall depends on the interaction between adhesion 
molecules on the surface of endothelial cells and their counter ligands on 
monocytes. Once resident in the arterial wall, the blood-derived inflammatory 
cells participate in and perpetuate a local inflammatory response. Monocyte 
differentiation into macrophages is achieved by MCP-1, and macrophage colony-
stimulating factor10 (M-CSF). Macrophage activation and the accompanying 
phenotypic change in function is achieved through scavenger receptors by 
oxidized lipoproteins (oxLDL) 11  
About 50% of infants in the first 6 months of life have regions within the coronary 
arteries containing lipids and macrophages12. It is unclear whether these regions 
represent pre-atheroma and will go on to produce overt atherosclerotic lesions. 
Lesion progression may result in multiple morphologies 13 14 and advanced 
lesions vary with respect to the proportion of lipids, thrombus, calcium and 
connective tissue. However inflammatory cells including macrophages are 
present in all lesions. Thus macrophages provide both a sensitive (in that they 
are present in very early lesions) as well as specific (they are not found in normal 
vessel wall) marker for atherosclerosis. 
 
 
 
 18
Macrophage Biology 
Macrophages are derived from bone marrow stem cells (promonocytes and 
promyelocytes). These precursor cells have little synthetic capacity and are not 
capable of cell division. They make up about 2-10% of the peripheral white blood 
cells. They have a mean diameter of 15-20 µm. After they are released into the 
blood as monocytes they may circulate for 1-2 days prior to migrating into tissues 
and differentiating into macrophages. Macrophages can survive for months within 
the tissue. Macrophages express different phenotypes including differences in 
phagocytic capacity and cytokine production and surface receptor expression 
based of the stimulus provided by the surrounding tissue. Macrophages are 
responsible for tissue remodeling during development and wound repair. They 
produce numerous cytokines, growth factors and proteases that aid the 
remodeling of the extravascular matrix and stimulate the recruitment of other cell 
types such as fibroblasts and smooth muscle cells. Again the mechanisms that 
are appropriate for wound healing have detrimental effects when they occur 
within the vascular media. Key cytokines produced by macrophages include 
interleukin 1β (IL-1β), tumor necrosis factor-α ( TNF-α), IL-10, IL-12 and 
transforming factor β (TGF-β)15. Macrophage-derived growth factors that have 
significant effect on the progression of atherosclerosis include fibroblast growth 
factors (FGF’s), platelet-derived growth factors (PDGF), which is a potent 
stimulator of smooth muscle cell growth, migration and differentiation. In addition 
to these processes which have the effect of initiating vessel wall thickening and 
stimulating a fibrotic, synthetic stimulus in smooth muscle cells, macrophages 
also secrete other materials which degrade and weaken the extravascular matrix 
within the forming fibrous plaque. Specifically, members of the matrix 
metalloproteinase (MMP) family of zinc-containing endopeptidases. 
Histochemical and genetic studies have shown an association of MMP-1, MMP-
2, MMP-3 and MMP-9 in destabilization of atherosclerotic plaque16, 17. Activated 
macrophages also secrete tissue plasminogen activator (tPA)  and urokinase 
plasminogen activator (uPA). Both of these products act to degrade fibrin and are 
thus involved in natural blood clot dissolution18. 
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 Mechanisms of Endocytosis in Macrophages 
Macrophages have evolved a number of mechanisms to internalize particles 19 
and solutes46. The 2 major methods are phagocytosis and  endocytosis.  
Endocytosis has 2 subgroups: fluid phase pinocytosis which does not involve 
surface receptors and, receptor-mediated endocytosis 20. Pinocytosis usually 
refers to the uptake of fluids and solutes 
by small vesicles (≤ 150 nm) and in some 
cases is a constitutive process. 
Receptor-mediated endocytosis 21 is the 
specific process by which 
macromolecules, viruses and small 
particles enter cells. Both pinocytosis 
and receptor mediated endocytosis use a 
clathrin-based mechanism and usually 
occur independently of actin 
polymerization. Phagocytosis involves 
the uptake of large particles (>0.5 µm) by 
means of an actin-dependent 
mechanism. Feridex, the iron particle 
under investigation in the present study has an individual size of about 100 nm 
Figure 2: Electron micrograph showing stages of endocytosis from receptor migration to 
vescicle formation and separation. (from Endocytosis, edited by Ira Pastan and Mark 
Willingham, Plenum Press, 1985.) 
Figure 3: Structure of  3 members of the 
class A scavenger receptor family. From 
web page of Dr. Siamon Gordon, 
dunn1.path.ox.ac.uk/~cholt/sgMSR.html)
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but is usually found as aggregates of multiple particles.  The above electron 
micrograph (figure 2) shows the process of endocytosis. Whether ingesting fluid, 
small particles or larger particles, the endocytotic part of the cycle usually begins 
at specialized regions of the plasma membrane called clathrin-coated pits, which 
occupy about 2% of the total membrane surface area. Clathrin-coated pits are 
rapidly endocytosed, with a life-time of about 1 minute. This constitutive, but 
regulated,  vesicle formation is one method by which the surrounding 
environment is sampled, and will likely be one route by which Feridex particles 
are internalized. Clatherin is a fibrous protein containing a heavy chain (180,00 
mw) and several light chains (20,000-40,000 mw). These molecules form a cage-
like lattice around the entire vesicle. The purified protein is a triskeleton; a three 
armed trimer. When polymerized, the coated pit becomes a coated vesicle and 
pinches off into the cytoplasm. 
 
In addition to constitutive pinocytosis, macrophages have a mechanism for 
recognizing specific cell surface structure and thereby concentrating extracellular 
molecules via the clathrin-coated pits. Trans-membrane proteins concentrated in 
the coated pits include Scavenger (the structure of 3 variations is shown in figure 
322), mannose, compliment and receptors for the Fc-portion of immunoglobulin 
IgG (Fc-receptors). Scavenger receptors are defined by their ability to 
endocytose modified forms of low density lipoprotein (LDL). This class of 
receptors was first described by Goldstein and Brown in 197923. In contrast to 
receptor-mediated endocytosis of unmodified LDL, which is regulated via a 
concentration dependent negative feedback system, scavenger receptors 
internalize modified LDL’s without regulation and result in creation of foam cells 
containing large amounts of cholesterol. At least eight macrophage expressed 
scavenger receptors have been identified using molecular cloning. They differ in 
structure, and can internalize a broad range of ligands. There is great diversity as 
to the receptor recognized ligands and include toxins and lectins, viruses, 
proteins and antibodies such as transferrin, LDL, and IgE. Also hormones and 
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growth factors are internalized via receptor-mediated endocytosis including 
insulin, glucagons, and platelet derived growth hormone.24 
 
Magnetic Resonance Imaging 
While magnetic resonance imaging (MRI) is a relatively recent development 
(introduced by Paul Lauterbur in 1973), the spectroscopic method upon which it 
is based was discovered in 1946. It is important to appreciate that the physical 
and biochemical structure information is still available using the MRI technique. 
 
When certain nuclei are placed in a static magnetic field (designated B0) they 
have, under proper conditions, the ability to absorb and reradiate electromagnetic 
energy. This “resonance” characteristic is the basis for signals generated in 
nuclear magnetic resonance spectroscopy and imaging. In order for the nuclei to 
interact with the magnetic field they themselves behave as small bar magnets. 
This property is limited to nuclei with an odd number of neutrons and protons 
defined as “spin”.   “Spin” is a fundamental property of nature like electrical 
charge or mass. Spin comes in multiples of 1/2 and can be + or -. Protons, 
electrons, and neutrons possess spin. Individual unpaired electrons, protons, and 
neutrons each possesses a spin of 1/2. In nuclear magnetic resonance, it is 
unpaired nuclear spins that are of importance. There are numerous elements in 
the periodic table that meet the basic requirements for investigation using 
magnetic resonance. However only a limited group exist in biological systems in 
sufficient abundance to permit detection. The table below lists the 7 most 
commonly investigated nuclei. The precession (Larmor) frequency is given as 
γB0/2π. Where the gyromagnetc ratio (γ) is the constant associated with a given 
nuclei. B0 is the static magnetic field strength and is expressed as MHz/T where 
T is Tesla equivalent to a magnetic field of 10,000 gauss. 
Table 1: List of 7 common nuclei used in magnetic resonance. 
NUCLEI  UNPAIRED PROTONS UNPAIRED NEUTRONS NET SPIN  (MHZ/T) 
1H 1 0 1/2 42.58 
2H 1 1 1 6.54 
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31P 0 1 1/2 17.25 
23Na 0 1 3/2 11.27 
14N 1 1 1 3.08 
13C 0 1 1/2 10.71 
19F 0 1 1/2 40.08 
 
Due to the high concentration of hydrogen protons in biological structures, clinical 
imaging is nearly exclusively based on the hydrogen nuclei.  In the magnetic 
field, the nuclei align with the magnetic field. Due to their gyroscopic properties, 
the spins rotate or precess around their axis and around the direction B0 at a 
small off axis angle. Based on a net spin value of ½, hydrogen can exist in 2 
energy states ½ and –½. By adding energy at the resonant or Larmor frequency, 
spins may transition from the low to high energy state. Energy is released into 
the local environment when they return to the low energy state. It is the efficiency 
with which this energy can be released and the local nuclei concentration that 
determines image contrast in acquired image data.                    
Figure 4: Schematic displaying 3D relaxation 
trajectory for the net magnetization vector (M). 
The standard notation for 
displaying the net magnetic 
vector under investigation 
indicates the direction of the B0 
field along the +z-direction 
(designated H in figure 4), and 
the direction of the net 
magnetization vector (M) at 
equilibrium also in the +z-
direction. Radio-frequency (rf) 
energy applied to the system 
results in rotation of M into the x-
y plane or into the –z direction. Figure 4 displays the vectors trajectory after 
application of sufficient rf energy (at the Larmor frequency) to rotate the vector 
into the x-y plane. Two components of “relaxation” to equilibrium exist. 
Immediately after the rf is applied (then turned off), the vector is rotated into the 
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x-y plane and does not contain a z-component. Relaxation results in progressive 
return of the z-component and rotation around the z–axis.  The rate of 
longitudinal component recovery is designated T1. T1 depends on how efficiently 
energy is transferred from the resonant nuclei to the rest of the lattice via random 
thermal collisions between the molecules. The vector displayed in figure 4 is 
made up of individual vectors that will have different rates of relaxation 
depending on their local environment (i.e. water versus lipids). Immediately after 
the rf pulse they are all in the same x-y position but rapidly move out-of-phase. 
T2 is a measure of the rate of decay of coherence among nuclei.  
Table 2: comparison of T1 and T2 relaxation times for biological tissues at 0.5T and 1.5T 
Tissue T2 (msec) T1(msec) at 0.5T T1(msec) at 1.5T 
Adipose 80 210 260 
Liver 42 350 500 
Muscle 45 550 870 
White Matter 90 500 780 
Grey Matter 100 650 920 
CSF 160 1800 2400 
 
The above table shows the difference in T1 and T2 among different tissues. It 
can also be seen that T1 is field strength dependent and increases with 
increasing B0. T2 is independent of B0.  
 
 
MRI Contrast Agents  
Effective MRI contrast agent fall into 3 
general classes: 1) Relaxation rate 
enhancers (T1 and, or T2); 2) 
Resonant frequency shift agents, or 3)  
Magnetic susceptibility agents, in such 
a way as to result in an observable 
change in local signal when imaged with the appropriate pulse sequence. The 
Figure 5: Chemical structure of the 
most common clinically used contrast 
agent: Gd-DTPA 
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contrast agent most widely used in MRI is a low molecular weight gadolinium 
agent.  Figure 525 displays the superimposition of minimized crystal structures 
(green) and the Genetic Algorithm predicted conformation (magenta). Gadolinium 
was discovered by J. C. G. de Marignac in 1880, who named the metal for 
Finnish geologist, J. Gadolin. This agent is a relaxation agent and is distributed 
primarily by blood flow alone providing no information regarding inflammation or 
the distribution of specific cell types. 
 
Metal ions such as Dy3+, Ho3+ and Eu2+ have significant unpaired electron spins, 
rapid electron spin relaxation characteristics and exhibit little effect of relaxation 
properties but result in a substantial shift of resonant frequency. 
 
There are a number of iron oxide particles undergoing phase II or III clinical trials. 
There is but a single iron agent approved by the FDA. It is approved for use as a 
liver MRI contrast agent and marketed under the trade name Feridex (Berlex 
labs, Wayne NJ). While the primary indication for these agents is a liver contrast 
agent, there are preliminary reports that they may identify sites of atherosclerosis 
by means of labeling macrophages. In that these iron agents represent a 
"process specific" contrast agent, it is critical that macrophages be characterized 
regarding endocytotic route, (i.e. is this a receptor mediated phagocytosis?) and 
factors regulating the extent and rate of particle phagocytosis. If uptake of 
particles varies significantly based on endogenous and or exogenous factors, 
interpretation of MR images produced after particle administration must take this 
into account. 
 
Mechanism of Magnetic Resonance Signal Alteration by Iron Oxide 
Table 3 adapted from "Principles of MRI Contrast Enhancement" R.C. Brasch 26 
shows electron sub-shell configurations for first-transition-series ions with 
corresponding spin quantum numbers. Generally the greater the number of 
 25
Table 3: Electron sub-shell configurations for transition metals with potential for use as MRI 
contrast agents 
Transition 
Series 
Electron Subshell Spin Maximum 
VO+2 3d1 1/2 
Ti+2 3d2 1 
Cr+3 3d3 3/2 
Cr+2, Mn+3 3d4 2 
Mn+2, Fe+3 3d5 5/2 
Fe+2, Co+3 3d6 2 
Co+2, Ni+3 3d7 3/2 
Ni+2, Cu+3 3d8 1 
Cu+2 3d9 1/2 
 
unpaired electrons the stronger the paramagnetic behavior and the greater the 
T1 and T2 shortening effect. In addition, the distance between the paramagnetic 
center and the protons affected, the tumbling motions of the paramagnet and the 
protons, and the rate of electron spin relaxation all combine to define the degree 
of T1 and T2 shortening and the final effect on signal 27.  
 
These metal ions reversibly bind a number of water molecules in their inner 
hydration sphere and exert their relaxivity effect. Unpaired electrons have 
magnetic dipoles that respond to an external magnetic field much the same way 
as a bar magnet. Paramagnetisim is characterized by the independent action of 
individual molecular magnetic moments. Feridex contains Fe3+ and Fe2+ in a 2:1 
ratio. Fe3+ contains 5 unpaired electrons. The general formula is Fe3+O3Fe2+O. 
 
Superparamagnetism can arise if the crystal containing regions of unpaired spins 
is sufficiently large that it can be considered as a thermodynamically 
independent, single-domain particle 28. Such a particle has a net magnetic dipole 
that is large or larger, compared to the sum of its individual unpaired electrons. 
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The T1 and T2 shortening arises as a consequence of interactions between the 
unpaired electrons of the para or superparamagnetic species and the hydrogen 
nuclei of water molecules. These interactions result in transfer of energy from the 
water molecules to their surrounding environment. 
 
Table 4: Current iron particles under investigation for use in MRI 
Specific Iron Particle Diameter  
Monocrystalline iron oxide (MION) overall:21 nm, core: 4-5 nm 
Superparamagnetic iron oxide particles 72 nm 
Magnetite albumin 1-5 µm 
Ultra Small Particles of Iron Oxide 18 nm 
Dextran coated Fe3O4 (Feridex) 27-30 nm 
Starch coated iron oxide (MSM) 0.1-0.5 µm 
Crosslinked starch coated iron oxide (DSM) 1.0-1.8 µm 
 
Description of specific particle  
The specific material used in this study is sold under the brand name Feridex and 
marketed by Berlex laboratories. It is packaged as a sterile aqueous colloid of 
superparamagnetic iron oxide associated with dextran. Chemically Feridex is a 
non-stoichiometric magnetite of average formula FeO1.44. As provided, each ml of 
the agent contains 11.2 mg of iron and 61.3 mg of mannitol at a pH of 5-9. The 
formulation also contains dextran (5.6-9.1 mg/ml) and citrate (0.25-0.53 mg/ml). 
The osmolality is about 340 mOsm/kg, specific gravity is 1.04 29. Figure 630 
shows a schematic representation of the structure created by the ferrous iron, 
Ferric iron and Oxygen as well as the magnetic domains with the crystal and 
idealized contrast agent particle. 30Previous data from Wessleder et al. 31 has 
shown that elemental iron contained in dextran-10 coated SPIO particles is 
slowly released and subsequently used for hemoglobin synthesis over the course 
of 2-40 days. 
 
Figure 6 : Scematic representation of  (A) crystal structure for SPIO, (B) presence of multiple 
random magnetic domains within crystal, (C) SPIO particle with multiple crystals in black and 
coating in grey.  
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Once internalized into a macrophage, particles follow an intracellular transport 
pathway from endosomes to lysosomes. Thus particles are exposed to a 
gradually decreasing pH as low as 4.5.32 In order to determine the eventual 
biological fate of injected iron nanoparticles, Skotland et al.33 tested the effect of 
incubating iron nanoparticles at a pH of 4.5 to 5.0 in the presence of dicarboxylic 
acid citrate to determine if iron particles are solubilized. At a pH of 4.5 iron was 
fully solubilized by 10 days. In less acidic environments this time increased 
significantly to 22 days at a pH of 5.0. In the same study, distribution of 59Fe 
particles was distributed 73% in the liver, 18% in the bone marrow and 5% in the 
spleen of rats 8 hours after administration. It was postulated that after iron is 
solubilized in the lysosome it traverses the cytosol, eventually making it to the 
mitochondria where it is used for heme synthesis. 
Surface Properties of Feridex Material 
In addition to size and particle charge, the properties of the coating on the iron 
oxide particles will influence the mode and extent of uptake by macrophages and 
other phagocytic cells. Jung 34 compared SPIO colloids consisting of 
nonstoichiometric magnetite crystalline cores coated with dextran T-10 (brand 
name Feridex, of the class ferumoxides), Ferumoxtran (also coated with T-10 
dextran but using a different method and ferumoxsil (coated with siloxane). 
Review will be limited to ferumoxides (Feridex).  
 
Figure 7: Fourier Transform Infrared Spectroscopy of 
Feridex showing presence of adsorbed Dextran-10  
In the work by Jung et al.34 
Fourier transform infrared 
spectroscopy  (FTIS) was 
measured with different 
nonoparticle types mixed with 
KBr, ground with an agate 
mortar and pestle and dried 
for 1 hour at 110 degrees C. 
Spectra were acquired over 
the range of 400 to 4000 –1  
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cm. All spectra were ratioed against KBr. Figure 7 shows a graph of the spectra 
plotting % Transmission versus Frequency. Spectra were displayed vertically for 
clarity. For comparison, spectra from uncoated particles and pure dextran T-10 
are included. 
 
Figure 8: X-ray Photoelectronic Spectroscopy of Feridex showing x-ray attenuation (750-
1000 eV) associated with surface layers of dextran 
 
Wavelength specific “bands” showed the presence of adsorbed dextran T-10. 
Bands of reduced transmission (ferumoxide) at ≈ 3400 cm-1 and ≈ 1600 cm –1 
resulted from νO-H stretching and deformation modes of dextran hydroxyl 
groups and physisorbed water. νC-H and δC-H vibrational modes are seen as 
dips in the %transmission at ≈ 2900 cm –1 and 1250-1460 cm –1. νC-O vibrations 
are seen as regions of reduced transmission at ≈ 1040-1150 cm –1.  
 
X-ray photoelectric spectroscopy (XPS) was used to determine the surface 
element composition of the nanoparticles.  Based on the spectral data (Figure 8), 
the mole percent of each studied element was determined. The table 5 was 
generated from data reported by CW Jung34. 
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 The large attenuation of the iron peaks (750-1000 eV) is caused by the presence 
of layers of adsorbed dextran on the nanoparticle surface. Fe peaks can be seen 
clearly in the spectra of the uncoated sample. Jung states that the slightly more 
pronounced iron peaks seen in the ferumoxides (Feridex) than in the spectra of 
the ferumoxtran suggestive of a thinner dextran coating on Feridex. 
Table 5 : Calculated surface composition based on chemical structure 
Peak Eb (eV) Area (%) Surface (%) Comment 
Fe 712.08 28.7 -  
2p3/2 710.00 64.1 6.6 Fe(III)-O 
 708.30 7.2 0.5 Fe(II)-O 
O, 1s 533.64 2.6 1.3 RCOO/C=O 
 532.48 49.3 24.2 Dextran—C-O 
 - - -  
 531.23 11.1 5.4  
 - - -  
 529.82 37.0 18.2 Fe-O2- 
 - - -  
C, 1s 288.65 3.9 1.7 RCOO/C=O 
 287.45 14.0 6.1 Dextran-O-C-O 
 - - -  
 286.05 57.7 25.2 Dextran-C-O 
 284.60 24.3 10.6 Alkly C 
 
710 eV binding energies of the Fe 2p3/2 photoelectrons are consistent with Fe3+ 
oxides (Figure 7, Table 5). There is also a weaker signal at 708 eV which is likely 
due to Fe2+ iron. The major component of the carbon 1s spectrum (286.1 eV) for 
the studied nanoparticles is attributable to the CHOH groups of the dextran. In 
principle, the reduction of x-ray peak intensities can be used to estimate the 
thickness (d) of the dextran coating. Based on the relationship: 
 
     d = n λcosθ 
 Where  λ is the photoelectron inelastic mean free path  
   θ is the electron takeoff angle 
   n is based on the photoelectron escape depth 
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Using a value of 3nm for λ, and 2 for n, a 3.3 nm thickness dextran coating in 
Feridex was estimated. Dextran T-
10  has a mass averaged 
molecular weight of  9400. It is 
produced by Leuconostoc 
mesenteroides strain B512. It is 
95% linear and due to multiple 
attachment sites to the iron oxide 
surface, its length of about 22 nm 
yields a 3.3 nm coating thickness 
(figure 9). This results in a 
predicted diameter significantly 
less than that determined by light scattering methods. Photon Correlation 
Spectroscopy (PCS) is a dynamic light scattering technique used to investigate 
dynamical properties of materials. The basic idea is to send in laser light with well 
defined properties (wavelength, polarization etc.) into a sample and investigate 
the properties of light scattered by the sample. With PCS the dynamical behavior, 
i.e. the auto correlation function, is directly obtained in the time domain. In 
dynamic light scattering experiments, the radius (R) of the particle is calculated 
from the diffusion coefficient (D) via the Stokes-Einstein equation, where k is the 
Boltzmann constant, T is the temperature, h is the solvent viscosity, and f = 6phR 
is the frictional coefficient for a compact sphere in a viscous medium. 35 
 
Figure 9: Model of dextran microstructure at iron 
oxide surface 
  
 
  
By definition then, the DLS measured radius is the radius of a hypothetical hard 
sphere that diffuses with the same speed as the particle under examination. This 
definition is somewhat problematic with regard to visualization however, since 
hypothetical hard spheres are non-existent. In practice, iron nanoparticles in 
solution are non-spherical, tend to aggregate and are dynamic (tumble), and 
solvated. As such, the radius calculated from the diffusional properties of a 
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nonoparticle is indicative of the apparent size of the dynamic hydrated/solvated 
particle. Hence the terminology, ‘hydrodynamic’ radius. It must be stressed that 
aggregation results in a distribution of aggregate particle size, not individual 
particle size. 
Static secondary ion mass spectroscopy (SSIMMS) is a very surface selective 
(<1 nm) method. Thus the presence of Fe-containing ions in the acquired spectra 
indicates that there is incomplete covering of the core iron particle by dextran. 
Further, the lack of dextran-Fe ionic fragments indicates the absence of a 
covalent bond between the dextran and iron oxide surface. Thus, the 3-5 nm 
dextran coating thickness reported by Jung is consistent with previous models of 
polymer coatings by Brant et al. 36 in which the dextran (figure 9) forms loops via 
focal interactions between the dextran chain and the iron oxide. The difference 
between the calculated dextran thickness calculated by XPS and light scattering 
measurements (the generally reported value for coated iron oxide particles) is 
due to variations in dextran hydration and conformation in aqueous solution (as is 
the case with light scattering measures) and solid state XPS measures. It was 
shown (Jung et al.34) that the dextran coating on Feridex is sparse and permits a 
greater degree of opsonification than other tested iron oxide nanoparticles. 
 
Bulk Chemical and Physical Properties of Feridex Material 
Superparamagnetic particles in the size range of Feridex have magnetic 
saturations between 5 and 90 electromagnetic units (EMU) per gram of oxide at 
25ºC and lose more than 90% of their magnetism when an applied magnetic field 
is removed.  Compared to gadolinium based contrast agents Fe compounds are 
more effective T1 and T2 relaxation agents. The following table is taken from the 
work of CW Jung et al. 37   
Table 6: Comparison of relaxivities between Feridex and Gd-DTPA 
 Relaxivity (mM s)-1 
Agent 1/T1 1/T2 
Feridex 23.7±1.2 107±11 
Gd-DTPA 4.5 5.7 
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Feridex provides a 5-fold increase in T1 relaxation and a nearly 18-fold increase 
in T2 relaxation as compared to gadolinium DTPA due to increased magnetic 
moment present in superparamagnetic materials.  
 
Feridex Particle Size Distribution 
The iron oxide used in the present study is in the form of a colloid with manitol 
and citrate. It has been previously shown that particle size is one of the 
determinants of macrophage uptake. However, the determination of "size" is not 
straightforward. Feridex contains groups of iron particles covered with low 
molecular weight dextran 38 39. Polycrystalline aggregate size can be expressed 
in a variety of ways, depending on the characteristic of interest and the technique 
of determining it. The size of Feridex as well as other iron oxide particles is 
generally determined using commercial particle sizing instruments such as 
Coulter, Brookhaven, Malvern or Leeds & Northrop. All of these instruments 
measure particles based on the quasi-electric light scattering and work well with 
certified latex standards or any monodispersed particle. In more complex 
distributions, particularly with broad distributions of non-spherical particles (such 
as Feridex) these instruments may give quite different diameter values for the 
same sample based on the assumptions used or selection of mathematical 
techniques. Diameters may be expressed as 40: 
 
average diameter 
number weighted average diameter 
surface weighted average diameter 
volume weighted average diameter 
z-average diameter 
Weighting factors applied to the numbers while averaging them include: 
number 
area 
volume or mass 
light scattering intensity 
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 Figure 10: Particle size differences based on 
method of measurement 
The most common method used to 
report particle size is that derived 
from light scattering techniques in 
which the average diameter 
expressed is the z-average diameter, 
derived as: 
 
                                                         
nidi
6
nidi
5  
 
Because of the dependence on the sixth power of the physical diameter, it is very 
sensitive to larger particles and may result in significant differences between 
mean and mode values. The intensity of light scattered by a system of particles 
with diameter d is proportional to the number of particles n, the square of the 
particles mass m and a particle form factor P(Ø), which depends on size, 
scattering angle, index of refraction and wavelength. Figure 10 taken from Jung 
et al.37 show the effect of size measurement method on the estimated size and 
size distribution of Feridex. 
 
Dextran coated particles were developed in order to increase blood residence 
time before being taken up by the reticuloendothelial system (RES) including 
liver, spleen, lymph nodes, bone marrow and lung, as was the problem with 
previous larger ferromagnetic particles. Feridex, is larger than paramagnetic ions 
which have the problem of rapid metabolism in the target organ. For the present 
study, the sub-micron size is particularly important in that they can pass through 
the capillary network and endothelial cell spaces 41 to reach macrophages in the 
vascular media. However it should be understood that these particles form 
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aggregates of multiple individual particles. This results in a wider range of 
effective size distribution.  
 
Pinocytosis: 
If soluble material cannot adhere to the surface of macrophages, it will be 
endocytosed in vitro via fluid-phase pinocytosis at the concentration that is 
present in the medium. If the material adheres to the cell's surface via its 
chemical properties (or via specific receptors 42 43 44) it will be selectively 
concentrated at the macrophage surface and endocytosed by adsorptive 
pinocytosis 45. 
 
Pratten et al 46 have shown that particle size, in addition to composition 
determines whether internalization will occur via "fluid-phase" endocytosis or 
phagocytosis. Particles ranging in size from 30 nm to 1100 nm were 
radiolabeled, and endocytotic index (microliter/106 cells per hour) measured with 
I-125 determined in the absence or presence of metabolic or cytoskeletal 
inhibitors. Rates of clearance (internalization) increased with increasing particle 
diameter. Particles of 30 nm diameter were endocytosed 10 times faster than a 
reference solute (polyvinylpyrrolidone, MW = 40k). Particles (polystyrene) of 100 
nm diameter were endocytosed 100 times faster than the reference. It was 
concluded that there is no radical discontinuity between pinocytosis and 
phagocytic uptake, but the contribution of phagocytosis steadily increases with 
increasing particle size. 
 
Using  horseradish peroxidase, the nonspecific fluid-phase marker of 
endocytosis, Montaner et al 47 investigated the effect of T-cell cytokines IFN -γ, 
IL-4, IL-13 and IL-12 on fluid phase endocytosis in primary human macrophages. 
Mannan was used to block mannose-dependent receptor uptake. Incubation of 
cells with IL-4 or IL-13 resulted in an increased uptake of 200% when the 
mannose receptor was blocked, and 350% when it was not. This indicates a dual 
pathway of internalization of the horseradish peroxidase. IL-10 and IFN -
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γ supressed uptake to < 25% of control. Macrophages were treated with test 
cytokines for 6 days and exposed to horseradish peroxidase for 60 min. Thus the 
normal constitutive fluid-phase uptake pathway is also regulated by macrophage 
activating cytokines and thus may alter uptake of iron oxide particles. 
 
Receptor Mediated Endocytosis 
The major difference with respect to phagocytic capacity and efficiency of 
"professional phagocytes" and the numerous other cells that have limited 
phagocytic capability is attributed to specialized phagocytic receptors.  
 
Only limited work has been performed characterizing receptor-mediated 
endocytosis of iron oxide particles. Complement proteins present in serum, 
normally opsonize bacteria for phagocytosis by the C3b or C3bi receptors on 
macrophages. Moore et al 48 and Bogdanov 49 have shown evidence that 
monocrystalline iron oxide (MION) particles bind plasma proteins and are 
internalized by macrophages. MION particles were incubated with citrate diluted 
rat plasma for 4h at 37º C. Using Western blot analysis, they demonstrated that 4 
major plasma proteins had been adsorbed including transferrin, fibrinogen, IgG 
and C3. Macrophage uptake of these proteins is via the transferrin-, Fc- , and 
C3- receptors respectively. They also found that the amount of surface bound 
dextran had a significant extent on the amount of plasma proteins bound to the 
iron particle. In a later study, the same group measured the macrophage uptake 
of opsonized, radiolabeled (I-125)  MION particles in rat macrophages and glial 
cells. Mion was opsonized in undiluted plasma prior to incubation with isolated rat 
peritoneal macrophages. Serial concentrations of opsonized MION (0-25µg/ 
150,000 cells)  were incubated for 1h at 37 degrees. Cellular uptake in 
macrophages and murine glial cells (control) demonstrated preferential uptake of 
opsonized MION in both cell lines. Uptake of opsonized (macrophages) MION 
averaged 6-fold higher than non-opsonized. However in glial cells, uptake was 
low and not different between MION preparations. They concluded that uptake of 
opsonized MION by macrophages is almost solely dependent on scavenger or 
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CR3- receptors and cannot be explained by elevated pinocytotic uptake in 
macrophages, since non-opsonized MION was taken up equally in both cell lines. 
Although not reported, the data indicate that the receptors used to internalize 
opsonized MION did not show evidence of saturation over the range of tested 
concentrations. 
 
In a study evaluating the macrophage uptake of cross-linked starch coated iron 
oxide particles (DSM, 1.0-1.8 µm). Fahlvik et al 12 used cultured murine 
macrophages (J774) to determine the uptake and toxicity of these particles for 
use as MR contrast agents in the reticuloendothelial system. These particles 
ranged in size from 0.1 to 1.8 µm. The J774 cell line is described as a reticulum 
cell sarcoma with the morphology, adherence and phagocytic properties of 
macrophages 50. Cells were grown in Dulbecco's modified Eagle’s medium 
(Gibco, USA) with 10% fetal bovine serum, benzylpenicilin (100 U/ml) and 
streptomycin (10 µg/ml) at 37 degrees and 5% CO2. Uptake capacity of J774 
cells was quantified by exposure to C-14 labeled iron oxide particles for up to 4h 
at 4 and 37 º C. Cells were incubated with either labeled DSM, hydrolyzed starch 
iron oxide particles (MSM) or unlabeled DSM particles. The difference between 
the iron oxide particles measured at 37º C and 4º C 51 was reported as the 
internalized fraction. The concentration of internalized, labeled particles reached 
a plateau by 3 hours (measurements were take at 1 hour increments). The 
plateau of phagocytosis (9-10 µg iron particles per 106 cells) was reported as 
similar to a report by Artursson et al.52 in which uptake was compared between 
resident and activated macrophages. In the Artursson study the difference was 3 
and 14µg iron particles per 106 cells. Fahlvik concluded that the tumor J774 cell 
line behaved similar to an activated macrophage cell line in regards to surface 
receptors and phagocytic capacity. 
 
Differentiation Between Pinocytosis and Phagocytosis 
Feature differences between these 2 routes of internalization will be used to 
systematically identify the route (or routes) of iron oxide internalization 53. 
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Pinocytosis has 3 features that may be used to distinguish it from phagocytosis. 
First, it takes place continuously, even in the absence of added ligands. Second, 
it is insensitive to the fungal metabolite cytochalasin B, which interferes with the 
function of actin filaments. Third, uptake by pinocytosis entails significant 
internalization of fluid or small particles. Phagocytosis also has unique features. 
First, it always requires the binding of the particle to the plasma membrane as a 
prelude to internalization. It should be noted that there are particles that readily 
bind but are only negligibly internalized. Second, particle ingestion is inhibited by 
cytochalasin B, implying an actin dependent mechanism. Third, the membrane of 
the phagosome, the initial vesicle that contains the particle, is closely apposed to 
the latter, so that only a small volume of fluid is taken up during phagocytosis. 
Combining this information with the known effects of cytokines and other 
exogenous agents it is expected that a potential route(s) for iron oxide particles 
may be elucidated. 
 
Factors Effecting Rates of  Macrophage Phagocytosis 
Early atherosclerosis, primarily fatty streaks, includes primitive macrophages and 
T lymphocytes. Prior to activation via inflammation, resident macrophages are 
immunologically quiescent. They have low oxygen consumption, low levels of 
major histocompatibility complex (MHC) class II gene expression, and little or no 
cytokine secretion. However they are phagocytic (at a reduced level) and 
chemotaxic and retain some proliferative capacity. Activated macrophages are 
defined as those possessing specific increased functional activity. There are 2 
stages of macrophage activation: "primed", with enhanced MHC expression, 
antigen presentation, O2 consumption, and reduced proliferative activity. 
Stimulating factor(s): TNF-alpha, IFN-alpha, IFN-beta, IL-3, M-CSF TNF-alpha 
can "prime" a macrophage. Activated macrophages show an ability to proliferate, 
high O2 consumption, maximal secretion of mediators of inflammation including: 
TNF-alpha, IL-1, IL-6, NO (from iNOS). The Murine J774 cell line identified in this 
project has been shown to behave as a constitutively activated macrophage. The 
macrophages that are located within the vascular wall in atherosclerosis are 
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activated. Two aims of the present study were to determine the extent to which 
endogenous factors such as the cytokines Interferon-γ (IFN-γ), IL-4, and 
exogenous factors involved in pharmacologic therapy such as HMG Co-A 
reductase inhibition 54 and angiotensin converting enzyme inhibition55 effect the 
rate and extent of iron oxide uptake based on their effect on other biomolecules.  
 
The ability to detect the presence of macrophages on MR images is not directly 
related to the number of macrophages present per unit volume, but the number 
of iron oxide particles per unit volume. Therefore it is necessary to understand 
the effect of endogenous and exogenous factors which could affect the time 
course of internalization after particle administration as well as the number of 
particles per macrophage. 
 
Endogenous Factors 
 Activated macrophages produce inflammatory cytokines, chemokines and 
reactive oxygen species. Transforming growth factor β1 (TGF-β1), a key cytokine 
for control of cell growth, extracellular matrix formation, and inflammation control, 
is secreted by many cells present in atherosclerotic plaque. Draude et al.56 
investigated the ability of these cytokines, at various concentrations, to influence 
both the expression and function of ScR-A, CD36 and LOX-1 in activated 
macrophages. They reported an approximately log-linear suppression effect on 
ScR-A and CD36 specific mRNA over increasing concentrations of TGF-β1 (2.5, 
5, 10, 20, 60, 80, and 120 pM). CD36 and ScR-A mRNA levels were reduced by 
20% by 20pM TGF-β1 and to 50% by 40 pM TGF -β1. Conversely, the mRNA 
levels of LOX-1 were significantly increased 50% by 40 pM TGF-β1. The 
functional relevance of mRNA up or down regulation was confirmed by 
incubation of cells with oxLDL which was internalized at a rate consistent with 
mRNA expression. 
 
 39
The divergent effect on receptor activity by individual cytokines were used in the 
present study to confirm or exclude specific receptor mediated pathways for iron 
oxide internalization. 
 
Exogenous Factors 
Pharmacological treatment of hypercholesterolemia has been successful in 
reducing clinical cardiovascular events and therefore has become a common 
therapy. One of the more common of this category is the class of 3-Hydroxy-3-
methylgluatryl coenzyme A (HMG-CoA) reductase inhibitors. They exert an effect 
by blocking the conversion of  HMG-CoA to mevalonate, a rate-limiting step in 
the biosynthesis of cholesterol. It is likely that patients undergoing evaluation for 
the presence of atherosclerosis may be taking this class of drugs. Thus, it is 
important that its effect on macrophage uptake of potential MRI atherosclerosis 
contrast agents (iron particles) be understood. Aikawa et al 57 recently reported 
that cerivatatin (an HMG-CoA reductase inhibitor) decreased the number of 
macrophages in cell culture in a dose dependent fashion.  Bernini et al 58 
investigated the mechanism of fluvastatin action on AcLDL endocytosis. Their 
data showed that endocytosis was down-regulated both in resident as well as 
activated macrophages. It was concluded that the decreased internalization of 
AcLDL was not related to a decreased expression of the scavenger receptor, 
based on data showing no decrease in cellular binding at 4º C. The effect of 
fluvastatin was seen to act independently on the receptor for AcLDL (although 
inhibition of endocytosis of other ligands was not investigated)  in that native LDL 
degradation was seen to slightly increase when AcLDL degradation was 
reduced. Other members of the statin family have shown similar effects 59. 
 
Losartan, an angiotensin II receptor antagonist, is widely prescribed as an 
antihypertensive medication. In addition to its blood pressure lowering effect, it 
has been shown to downregulate CD36 (an oxidized LDL receptor) expression 
by 54% 60. This resulted in a 78% reduction in oxidixed LDL macrophage 
association and a 21% reduction in oxidized LDL degradation. No data exists on 
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whether other receptor mediated or fluid-phase mechanisms of endocytosis are 
effected. Therefore its effect on iron oxide internalization is unknown. 
 
Clinical Magnetic Resonance  Imaging 
The imaging parameters used in the present study to characterize iron oxide 
nanoparticles differ substantially from than those applied to patient imaging. The 
major differences arise from the need to account for motion and blood flow within 
the vessel of interest. A typical vascular exam will begin with a series of localizer 
images meant to identify the location and orientation of the target vessel with the 
patient in the supine position.  Clinical scanners use a large radio-frequency coil 
built into the scanner bore transmit the RF pulses and a smaller coil placed on 
the patient to receive the MR signal . Surface coils improve signal-to-noise due to 
their proximity to the target but also limit the area that may be imaged. Three 
types of motion exist. Respiratory motion results in cyclic motion of the chest 
heart and great vessels. Failure to account for this motion will result in blurring 
and ghost artifacts, primarily along the phase encoding direction. Cardiac 
contraction produces 3D motion of the heart and associated great vessels. 
Current scanners acquire data fast enough to permit images to be acquired 
during a brief suspension (10-20sec) of respiration. Cardiac motion is accounted 
for by synchronization of acquisition to the patients’ electrocardiogram (ECG). 
This creates an effective repetition time (TR) which is a multiple of the patients 
cardiac cycle length. In practice imaging efficiency is maintained by acquiring 
multiple anatomic locations during each cardiac cycle.  Finally, overall patient 
movement is a minor issue as long as the acquisition period is limited to under a 
few minutes.  
 
Imaging of the vessel wall must deal with blood flow within the vessel. In the 
proximal arteries it is pulsatile, while venous and more distal arteries display an 
essentially constant blood flow velocity. Blood flowing through different spatial 
encoding gradients will cause the signal to be incorrectly mapped to the wrong 
position as a ghost artifact. Refocusing gradients have been used to correct for 
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this. Recently the majority of vascular imaging methods use a non-selective 
inversion pulse immediately followed by a slice selective reversion RF pulse. This 
results in blood prepared so as not to produce signal to flow into the imaging 
plane, and improve visualization of the vessel wall. A limitation of these “black-
blood” sequences is that the labeled macrophages are primarily on the 
endothelial surface. If the region of signal loss due to Feridex is immediately 
adjacent to the dark vessel lumen, the region of vascular uptake may not be well 
appreciated.  
 
All of these methods have the effect of changing the “weighting” of the pulse 
sequence. Due to the T2 shortening of the Feridex agent sensitivity to detecting 
the agent increases with increasing TE interval. Gradient recalled echo (GRE) 
sequences which use a single RF pulse followed by gradient reversal to create 
the echo signal are also sensitive to iron agents due to the fact that gradient 
rephrasing does not eliminate the dephasing effects of magnetic field 
inhomogeneities, such as iron particles.  In practice, TE’s longer than about 60 
msec are sensitive to any local motion and are inherently low in SNR whether 
they are in a spin echo or gradient echo sequence.  
 
Spatial resolution is limited by 2 factors, available signal and the relationship 
between the selected field-of-view (FOV) and the sensitive volume of the surface 
coil. Ideally one would like to spatial resolution that is high relative to the 
structure being imaged. Arterial wall thickness varies from less than 0.5 mm in 
the coronary arteries to about 2 –2.5 mm in the aorta. The voxel size is 
determined by the FOV and number of pixels in the matrix. Present clinical 
scanners use matrix sizes of 2562, 5122 and 10282. The cross-sectional 
dimensions (anterior-posterior (AP)  to left-right (LR)) of phased-array surface 
coils is dependent on the size of the patient, usually 25 cm AP, 32 cm LR. If the 
selected FOV is smaller than the signal producing dimension, aliasing or “phase-
wrap” artifact will incorrectly map image data extending beyond the FOV. 
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Combines with signal-to-noise constraints, practical resolution is presently limited 
to >500 microns.  
 
Thus the lower limit of detection calculated in the present study using phantom 
and calculated data, is likely far lower than that which can be achieved given the 
constraints of actual patient imaging.  
 
 
Previous Imaging Studies 
While use of iron oxide particles has been used for some time for liver imaging, 
application in atherosclerosis is quite new. The only in vivo studies have been in 
rabbit models of atherosclerosis. In Watanabe Hereditable Hyperlipidemic 
(WHHL) rabbits, Schmitz et al.61  used this established model of atherosclerosis 
in order to evaluate the effect of intravenous administration of iron oxide particles 
on MR images acquired using a standard clinical imager and confirm the results 
with post mortem histology. The particle used was a carboxydextran-coated iron 
oxide with an overall diameter of 25 nm. Four groups were studied: Group 1, 
WHHL controls: no contrast agent; group 2: 50µmole Fe/kg, with an 8-hour post 
contrast delay; group 3: 50 µmole Fe/kg, with a 24-hour delay; and group 4: 200 
µmole Fe/kg dose with a 48-hour post contrast delay. Imaging parameters were 
set to produce moderate T2* weighting while maintaining the enhanced luminal 
blood signal attendant with standard gradient echo methods. Prior to 
administration of the iron agent both blood and aortic wall produced uniform 
"bright" signal. Aortic cross sections were acquired using 75 contiguous 2 mm 
slices. As expected, focal regions of signal loss were not observed in the control 
group. The best correlation (Spearman rank correlation coefficient of 0.78, 
p=0.0007) was reported for group 4. Using RAM-11-antimacrophage stain was 
used to confirm the presence and location of macrophages. Prussian blue was 
used to identify the location of iron particles. Iron particles were seen both 
associated with macrophages but also in regions of the intima devoid of 
macrophages. The authors concluded that increased endothelial permeability, a 
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known functional characteristic of atherosclerosis account for this finding 62.   The 
percentage of particles found NOT to be associated with macrophages was not 
reported. It is likely that the timing from administration to analysis would affect 
this value.   
 
In a study using a similar animal model but smaller iron oxide particle (18 nm) 
Ruehm et al.63 evaluated the performance of ultrasmall particles of iron oxide 
(USPIO) as a marker of macrophage activity. This group imaged the rabbit aorta 
in cross section using a 3D T1 weighted pulse sequence. Images were acquired 
each day after administration of 1 mmole Fe/kg for 5 days. Images were 
analyzed for signal intensity with the aortic lumen and vessel wall. New Zealand 
White rabbits were imaged in the same manner and used as controls in that they 
do not spontaneously develop atherosclerotic disease of the aorta. Histochemical 
staining (Prussian blue) and EM were used to identify the location of the USPIO. 
Signal intensity in the lumen was reduced for the first 3 days after USPIO 
administration due to the T2 shortening effect of this agent at high concentration. 
By day 4 signal had increased and provided good contrast between aortic wall 
and lumen. On days 3-5, focal regions of signal loss were observed in the aortic 
wall of WHHL rabbits but not in controls. It was stated by the authors that gross 
post mortem inspection of the aortic walls of WHHL as well as control rabbits did 
not reveal and obvious irregularities. (the example images shown in the text did 
not support this statement.) Histopathology showed marked uptake of Fe 
particles in macrophages embedded in atherosclerotic plaque in all WHHL 
animals. The authors did not discuss the presence of iron particles not 
associated with macrophages. Electron microscopy identified myosin filaments 
within the USPIO containing macrophages and concluded that the macrophages 
were of smooth muscle cell origin. Further foam cells filled with fat molecules 
were found not to contain USPIO particles. No rigorous attempt was made to 
match regions of signal loss on MR images with histopathologically confirmed 
iron particles or macrophages.  
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Objectives and Expected Significance: 
The overall objective of this project is to evaluate iron oxide particles as MRI 
markers of inflammation in atherosclerosis by way of their active internalization 
by macrophages. The specific aims are to : 1) determine the baseline time 
course of particle uptake in macrophage cell culture incubated with increasing 
concentrations if iron oxide particles.  2) Determine the effect of cytokines ( IFN-γ 
and IL-4) on the rate an extent of iron oxide internalization. 3) Determine the 
effect of exogenous agents (pharmaceuticals) including HMG-CoA reductase 
inhibitors and angiotensin II receptor antagonists on the regulation of particle 
uptake. 4) Determine the effect of the mannose receptor blocker mannan. 5) 
Determine the effect of the cytoskeleton inhibitor cytochalasin B on SPIO uptake 
and 6) Determine the minimum concentration of macrophages, per unit volume, 
required for detection by MRI.  
 
These results will determine the potential sensitivity and specificity of iron oxide 
particles in detecting atherosclerosis. Specifically, if it is determined that uptake 
can be significantly inhibited by specific cytokines known to be present in 
atherosclerotic plaque, or common drug therapy, then the absence of the 
contrast agent effect could not be interpreted as conclusive evidence for the lack 
of macrophage presence. However if there exists a level of constitutive 
macrophage uptake that would reach the level of MRI delectability, local 
stimulation of uptake induced by cytokines might be used to map macrophage 
activity as well as location.   
 
Experimental Methods: 
Statistical Analysis 
Reported results are expressed as mean ± standard deviation. ChromaVision 
area for the portion of the color spectrum specific for nuclear orange and blue 
associated with iron within the cell cytoplasm was expressed in µm2. Three 
circular regions (79206 µm2) were analyzed in each chamber. Statistics were 
performed using SigmaStat version 2.1 software (SPSS Inc, Chicago, IL). 
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Orange and blue area within each ROI was reported as either raw area (µm2) or 
percent of ROI area. To test the significance of treatment, SPIO concentration 
and interaction between the two on macrophage uptake of SPIO, 2-way analysis 
of variance was applied to the raw area data. Post hoc multiple comparisons 
between individual treatment and SPIO groups was performed using the Tukey 
Test. P-values <0.05 were considered significant. Cell density comparisons 
between control and treatment used a 2-tailed students t-test. When cell density 
was not the same between treatment and control blue area was corrected based 
on cell density and ANOVA performed on corrected values. Linear regression 
analysis was used to validate ChromaVision based cell density analysis against 
direct cell counting. This analysis was also used to determine the SPIO dose-
macrophage iron uptake relationship and SPIO concentration-MRI signal 
relationship. 
 
Macrophage Cell Culture: 
The murine macrophage cell line J744A.1 is described as a reticulum cell 
sarcoma with the morphology, adherence and phagocytic properties of 
macrophages 50. The J774 cell line has been used extensively for investigation of 
pinocytosis and receptor mediated phagocytosis64,65,50. Macrophages acquired 
from American Type Culture (Manassas, VA), were seeded into 75cm2, cell 
culture flasks (Costar, USA) containing 20 ml's of  Dulbecco's modified Eagles 
medium (Gibco, USA) with 10% fetal bovine serum, benzylpenicilian (100U/ml) 
and streptomycin (10 µg/ml) at 37º C and 5% CO2. The macrophage 
concentration was determined by use of a hemocytometer (Fisher Scientific). 
Beginning with an initial cell colony from American Tissue Culture, additional 
cells were propagated in 75 cm2 tissue culture flasks and frozen to insure a 
secure supply of cells from the original colony. By their nature, macrophages are 
uniquely adherent cells. The usual method of trypsin-EDTA and PBS are 
ineffective in removing adherent cells. Pieser L, et al. 66 describes the method 
applied to the present study. Medium was removed and cells washed with 1X 
PBS (x3). A detachment buffer made-up of 10-15 mM Lidocane-HCL (Sigma 
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Chemicals) and 10 mM EDTA in 1% PBS was added to the flask for 5-15 min 
followed by cyclic pipetting of buffer in order to dislodge the cells. Once cells 
have released from plastic flask, 10 ml of medium (including serum) was added 
to halt the effect of the lidocaine. Cells were centrifuged at 1500 rpm for 5 min. 
Cells were then resuspended in medium, counted and prepared for incubation 
with iron oxide and other test material. Initial dilutions of 5,000, 10,000 50,000, 
and 200,000 cells per 1.7 cm2 chamber surface were incubated for 24 hours, 
rinsed with cold PBS to remove any non-adherent cells, then fixed with 3% 
gluteraldahyde. 
 
Baseline Uptake of Iron Oxide Particles  
Macrophages are highly efficient at pino and phagocytosis. Determination of 
baseline iron oxide "time" and "dose" relationships were performed with 
incubation times of 10 20, 40, 80, 240, 360 and 480 min. at concentrations of 1, 
10 and 100 µL stock Feridex per ml of medium. Chamber slide systems 
containing either 4 or 8 wells in which the wells can be removed leaving a 
standard glass microscope slide were used for all experiments. Cells were 
cultured for 24 hrs prior to addition of iron after washing with PBS to remove any 
non-adherent cells. Cells were rapidly cooled to 4º C using cold PBS in order to 
arrest uptake. The cell membrane is not fluid enough at 4º C to permit particle 
internalization. Medium containing Feridex was removed, cells washed with 4º C 
PBS and fixed for at least 8 hours with 3% glutaraldehyde.  
 
Establishing the Route of Internalization 
In order to determine the route of particle internalization, baseline measurements 
will be performed using medium with and without cytochalasin B. This agent 
interferes with the function of actin filaments. It has been shown previously by 
Weiss et al 67 that phagocytosis but not pinocytosis is inhibited by this agent. The 
iron particle under investigation is coated with Dextran-10, which may effect its 
endocytotic route. To determine the role of the mannose receptor in iron uptake a 
group of cells were pretreated with 1.0 mg/ml mannan in standard Dulbecco’s 
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Modified Eagle’s Medium (DMEM, American Type Culture Collection, Manassas 
VA) with 10% FBS. This has been shown to effectively block this receptor.46 
Opsonification is another potential route of iron particle internalization.68,69 This 
route of endocytosis was examined by measuring cell-iron uptake using medium 
without the standard 10% FBS. HMG CoA reductase inhibitors (“statins”) are 
know to affect LDL receptor expression and activity.7071 This route will be 
examined in cells treated with different concentrations of mevinolin. 
Description of Histological Stains 
The most common application of Acridine orange (3,6-dimethylaminoacridine) is 
that of a fluorescent probe for biological activity in live cells.  In the present study, 
this stain was used based on its empiric differentiation between cytoplasm and 
macrophage nucleus (using visible light) and its color spectrum compared to 
Prussian blue. In fixed cells the acridine orange dye cation stains acid 
components including acidic mucopolysaccharides, mast cell granules, and 
nucleic acids. This stain is a weak base that is readily soluble in water. Lerman 72 
showed that acridine orange forms a complex between the acridine orange 
amino molecule with the nucleic acid base pairs. The difference in nucleic acis 
concentration between the cytoplasm and macrophage nucleus may account for 
the observed visible light color pattern. The method used includes: 
 
Stain Solution 
Aridine orange (0.1g/L of 0.5M Acetate buffer, pH 3.7@25ºC) 
 
Method 
1. Fix slide with methanol for 2 minutes and allow to air dry.  
2. Flood slide with Acridine Orange Stain for 2 minutes.  
3. Rinse thoroughly with tap water and allow to air dry.  
 
 
 
 48
The commonest method for demonstrating iron is Perls' Prussian blue stain, 
sometimes called Perls' acid ferrocyanide reaction. The acid ferrocyanide 
reaction of Perls' Prussian blue involves treatment with acid (usually 
hydrochloric) to release ferric ions from tissues. These are immediately captured 
by replacement of the cation of potassium ferrocyanide by the ferric ion, forming 
insoluble ferric ferrocyanide which then precipitates giving rise to the blue color. 
This is an extremely reliable process, and quite sensitive. Very small amounts of 
iron may be demonstrated microscopically. The method includes: 
Solution A  
Potassium ferrocyanide 2g.  
 
Distilled water 100 mL.  
 
Solution B  
Hydrochloric acid 2 mL.  
 
Distilled water 98 mL.  
 
Method 
1. Bring sections to distilled water.  
2. Place in a freshly made equal parts mixture of solutions A and B for 20 
minutes.  
3. Rinse well with distilled water.  
4. Dehydrate with ethanol, clear with xylene and mount with a resinous 
medium.  
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Quantification of Iron Oxide Uptake by Macrophages 
Fixed cells were first stained with Acridine Orange then counter-stained with 
Prussian blue. These stains occupy significantly different regions of the color 
spectrum and can thus be analyzed without spectral "spillover". The portion of 
the color spectrum occupied by cytoplasmic iron stained with Prussian blue, and 
nuclei stained with acridine orange was defined by the band of hue, luminosity 
and color saturation sufficient to 
localize the selected color, hue 
combination in the desired location on 
multiple slides. 
For Acridine Orange, the values for 
each variable were: hue (228 high, 16 
low); luminosity(145 high, 49 low); 
saturation(149 high, 58 low). For 
Prussian Blue the values applied were: 
hue(217 high, 28 low); luminosity(175 
high, 15 low); saturation(78 high, 6 
low). These values produced a narrow color “acceptance” window specific for the 
cells, iron and staining method. All cells were stained in exactly the same way, 
and the above values were used to determine the area of the slide (µm2) 
automatically designated “iron” or “cell”.   Localization was further tested in slides 
not treated with Feridex, but treated with the 2 stains. Using a ChromaVision®  
automated cellular imaging system (figures 11,13) a region containing >100 cells 
were identified for analysis at 40x -60x magnification. The identified regions were 
digitized. Regions containing blue iron particles identified manually in order to 
"teach" the system the wavelength and variability of the Prussian blue stained 
particles. The same process was repeated for the orange stained nucleus and 
cytoplasm. The relative amount of iron particles per cell is then calculated by 
taking the ratio of the area (µm2) to the total cell area (µm2). The number of cells 
in the field will also be recorded. Three separate fields were analyzed within each 
slide chamber location and this data used for statistical comparisons. 
Figure 11: ChromaVision microscope with 
digital camera and automated stage. 
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The ChromaVision Automated Cellular Imaging system (ACIS) is an automated 
microscopy and computerized image processing system that can detect, count 
and classifies objects of interest based on color, size or shape. Specifications 
include an automated microscope having objectives with magnification of 4X, 
10X, 20X, 40X and 60X. The microscope is interfaced to a Sony 3-Chip full color 
digital camera. The slide stage is computer controlled and may be moved in  X, Y 
and Z (focus). The camera assembly is interfaced to a Windows NT 4.0 
workstation equipped  with a flat screen monitor having a resolution of 
1280x1024 pixels. The optical resolution is listed as 0.0625 µm2 per pixel or 160 
µm x 120 µm per field-of-view. Once a color threshold (hue, luminosity and 
saturation) is selected, these values may be stored and cells on the current or 
other cell slides highlighted to show the regions meeting the selected color 
criteria (see figure 12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Grey scale representation showing regions identified as iron in black, and regions 
identified as cell nucleus in light grey 
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 a.b.
c.
d.
 
Figure 13: ChromaVision display screen. a. shows stained cells in one of 8 chambers. B. shows 3 circular 
ROI’s used for cell density and iron uptake. c. output of orange and blue area. D. enlargement of sub-region 
used to evaluate staining and identify potential image artifacts. 
 
Magnetic Resonance Relaxation Time Measurements 
Measurements were performed on a GE clinical MRI at Allegheny General 
Hospital operating at 1.5 T.  Serial dilutions of Feridex were suspended in 2% 
agar and placed in 50 ml centrifuge tubes. Concentrations included: 0.0 µM 
(control), 0.00214 µM, 0.00427 µM, 0.00855 µM. 0.0179 µM, 0.0342 µM, 0.0684 
µM, 0.137 µM, 0.273 µM, 0.547 µM, 1.094 µM. According to data provided by 
Advanced Magnetics (the developer of Feridex) light scattering methods tend to 
overestimate the "actual" size of iron oxide particles.40 Advanced Magnetics has 
estimated the average size of Feridex to be 20nm.40 Based on this size it is 
estimated that a milliliter of Feridex contains 4.2 x 1015 dextran-coated particles. 
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In that there is potential for the particles to settle prior to agar solidification, cross 
sectional images at the top middle and bottom of the tube will be acquired and 
mean signal compared using ANOVA. The T1 relaxation time was quantified by 
calculation of nine data points generated by the inversion-recovery method 
including Time-to-inversion  (TI) of 50, 100, 200, 400, 600, 800, 1000, 1400, and 
1600 msec. The T2 relaxation time was measured from ten data points 
generated with a Carr-Purcell-Mieboom-Gill sequence including time to echo  
(TE) of 14, 25, 50, 75, 100, 200, 400, 800, 1600, and 1900 msec Field-of-view 
(FOV), slice thickness and matrix size will be selected to match that commonly 
used in clinical vascular exams. Using these data an "optimal" set of parameters 
was defined. In vivo imaging parameters are constrained due to the need for 
electrocardiogram (ECG) gating which predefines the effective repetition time 
(TR) as being some multiple of the cardiac cycle length. This interval of 500-1000 
msec corresponds to a heart rate of between 120-60 beats-per-minute.  Further 
excessively long TE's may result in image blurring. Therefore, based on the 
"ideal" in vitro parameters, potential in vivo parameters will be tested for linearity 
of the concentration-signal intensity relationship. 
 
In vivo, a number of factors affect the lower limit of detection of iron oxide 
particles. Macrophages are not uniformly distributed within the imaged tissue. 
Further, macrophages are smaller than image voxels and can internalize a large 
number of iron particles. The effect of voxel size will be determined by acquiring 
images using identical parameters over a range of voxel sizes. Finally as 
previously stated, the effect of the iron oxide is limited to protons in their 
immediate vicinity. If water exchange across the macrophage membrane is slow 
relative to imaging speed, the number of effected protons would be reduced 
compared to that of an unrestricted environment. This could affect the magnitude 
of signal change observed. Based on imaging serial dilutions of Feridex-loaded 
gel, the lower limit of MRI detectability was estimated. 
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Results 
Magnetic resonance Imaging 
Figure 14 is a T1 weighted image of a subgroup of gel filled tubes. T1 weighting 
minimizes the effect of the iron agents and permits visualization of all tubes with 
the exception of those 
with the highest 
concentration. Signal 
intensity was measured in 
each tube over a range of 
Feridex concentration of 
0.0 µM (tube 1), 0.002 µM 
(tube 2), 0.004 µM (tube 
3), 0.009 µM (tube 4), 
0.017 µM (tube 5), 0.034 
µM (tube 6), 0.068 µM 
(tube 7), 0.137 µM (tube 
8), 0.237 µM (tube 9), 
0.547 M (tube 10), 1.09 
µM (tube 11). Figure 15 
plots the raw signal at 
each level of the gel-tube phantom for each concentration. In general, the signal 
was similar between levels. However it was noted that the control tube showed a 
trend toward greater signal at the bottom of the tube. 
Figure 14: T1 weighted cross sectional image of tubes 
containing gel-Feridex material. Top left column is control, 
signal drops with increasing iron.  
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This is consistent with the "coil effect" in which the RF receiver coil is more 
sensitive at the surface of the coil. To correct for this effect the signal was 
normalized by a factor, based on signal intensity at the 3 locations in the control 
tube which would equalize the signal across the control tube. These data are 
shown in figure 16. It was concluded that the Feridex was evenly distributed 
within the tubes, and a single location could be used for signal analysis. 
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 Figure 17 shows a representative cross-sectional spin-echo (SE) image with a 
TE of 50 msec. Loss of signal in all tubes of the third column and the lower rows 
of the second column is related to the increased iron oxide concentration and 
corresponding deceased T2. Figure 18 is an inversion prepared SE sequence 
with a time to inversion of 100 msec. The loss of signal in the center row of the 
center column corresponds to a TI of 700 msec which represents a gel T1 of 
about 1000 msec. 
Figure 15: Plot of raw signal intensity by phantom position and iron concentration. T1-
weighted image acquisition. 
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Figure 17: T2-weighted image showing greater 
signal loss in iron containing tubes compared with 
T1-weighted image (Figure 3 ). 
 
 
 
 
 
 
 
 
 
 
In order to quantify the T2 shortening effect of increasing concentrations of iron 
oxide particles in the gel material, T2 was measured using the Hahn spin echo 
method. Figure 19 displays the relative signal for each iron concentration over  
0
0 .2
0 .4
0 .6
0 .8
1
1 .2
0 0 .0 3 4 0 .0 6 8 0 .1 3 7 0 .2 7 3 0 .5 4 7 1 .0 9
To p
M idd le
B o tto m
Iro n  C on ce n tr a tio n  ( µ M )
Figure 16: Signal intensity normalized to control to correct for inhomogeneity of surface coil 
sensitivity across tubes 
Figure 18: Spin echo image with 180 degree 
inversion pulse 100 msec prior to sequence. 
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multiple time-to-echo (TE) intervals. The vertical axis is relative signal intensity, 
the horizontal axis is TE in msec. It can be noted that at higher iron concentration 
only the early part of the curve is linear. Signal was compared to background and 
data points not significantly above background were not used for curve fitting or 
T2 determination. T2 was determined by determining the slope of the natural log 
of signal intensity versus TE. 
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Figure 19: Plot of signal over different TE intervals, and for each iron concentration. These data used to 
calculate T2 shortening effect of iron particles. 
 
 
 
 
 
 
 
To determine iron oxide dependent changes in T1, the inversion recovery 
method was used. Figure 20 shows the signal versus time-to-inversion (TI) for 
the various iron concentrations. Clinical scanners are designed to produce 
images and the sign of the signal data is not preserved. As can be seen in figure 
20, signal for each phantom declines as the inversion time is increased, but then 
regrows after the zero value is reached. As is the case for most analysis, signal 
from tubes with high concentrations of iron oxide produce negligible signal due to 
the large T2 shortening effect. This could be overcome using ultra-short TE 
intervals, however these sequences are not available on clinical scanners. 
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Figure 20: Signal intensity as a function of inversion time and iron concentration. 
Signed values were determined by analysis of raw (pre Fourier transform) and 
are displayed in figure 21. The relationship between signal intensity, TI and T1 is 
given as:  
 
Signal ∝ 1 − 2exp − TI
T1
 
  
 
  
 
  
 
  
 
 
From this relationship it can be appreciated that at the TI where signal =0.0, T1 = 
TI/ln 2. The linear regression was determined for each iron concentration and the 
exact time of minimum signal determined by setting signal to 0.0. 
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Figure 21: Plot of signed values of signal intensity. Zero-crossing is used to calculate T1 
relaxation time for each iron concentration. 
Figure 22 shows that at low iron concentrations (0.0 - 0.0021µM),  T2 changes 
are more significant than T1. While at high concentrations (0.0086-0.034µM) T1 
changes more rapidly than T2. In that human application will likely occur at the 
lower concentrations, these data would indicate that use of T2 weighted image 
sequences would produce more signal change, for the same change in iron 
concentration, than T1 weighted sequences at low iron particle concentrations.  
 
While the T1/T2 values of the gel phantom are useful in determining the effect of 
iron oxide on relaxation parameters, these values are significantly greater than 
the 500-800 msec T1 measures in actual vascular wall.  Further, the acquisition 
parameters used to quantify the gel's T1 and T2 are not applicable to human 
studies in that such studies must be synchronized to the patient’s heart cycle 
(700-1200 msec). Therefore the gel tubes were rescanned using conventional 
imaging sequences and physiological TR and TE intervals. In practice, TE's 
above 50-60 msec result in image blurring due to motion. Figure 22 shows the 
signal-iron concentration curves for a group of standard clinical acquisition 
sequences including standard SE with TE = 14, 25 and 50 msec. 
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Figure 22: Summary of calculated T1 and T2 values for the tested iron particle 
concentrations. At lower concentrations T2 effects dominate, while at higher concentrations 
T1 shortening can be observed. 
 
Fast spin echo (FSE) acquires multiple echos per heart cycle as a means of 
reducing acquisition time. Two, 8, and 16 echo's per cycle were tested. It should 
be noted that use of multiple echo's results in restriction on selection of TE. Thus 
T2 weighting is not equivalent between tests. An ideal contrast agent will have a 
predictable, if not linear signal-concentration relationship. Figure 23 shows 
significant non-linearity. In fact, equivalent signal is observed at multiple 
concentrations for a given imaging sequence. Only the most T2 (TE=96 msec) 
shows reasonable linearity. In order to understand this result Simulations were 
performed using the relationship between T1, T2, TR and TE given by: Signal (S) 
∝ [1-exp(-TR/T1)] exp(-TE/T2). 
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Figure 23: Signal-concentration relationship for common clinical pulse sequences. Significant 
non-linearity may be observed. 
Figure 24 compares the signal-iron concentration relationship for four T1, T2 
relaxation value pairs. The 1600/1000 predicts a similar non-linear relationship to 
that observed in the gel phantom study (Fig 23). As the T1/T2 values are 
reduced more toward that know to exist in the vessel wall (i.e. 600/200), the 
relationship becomes significantly more linear. In order to confirm this prediction 
a limited set of gel tubes were prepared including Gd-DTPA, a low molecular 
weight (938) agent which shortens both T1 (estimated as 505 msec) and T2. 
(estimated as 158 msec). Figure 25 displays the signal-concentration relationship 
using a TE of 60 msec and a TR of 800 msec. This confirms that the relationship 
between iron oxide concentration and signal change is dependent on the 
background T1 and T2 relaxation times. Nonlinearity exists when T1 and T2 are 
significantly longer than those observed in the biological system under 
investigation. 
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Figure 24: Simulated signal-iron concentration curves generated to determine the effect of initial 
T1 and T2 value on curve shape. More physiological T1 and T2 values result in a more linear 
relationship. 
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Figure 25: Experimental data showing the signal-iron concentration relationship using physiological 
image acquisition and phantom values. Signal-iron concentration relationship shows improved 
linearity. 
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 Finally, the effect of voxel size on the signal-concentration relationship was 
measured using the second gel phantom set. Figure 26 shows no significant 
difference in signal between voxels ranging in volume from 0.34 to 2.25 mm2. It is 
accepted that the iron oxide distribution used in this study was evenly distributed, 
with diffusion times quite unlike what may be expected in the actual vessel wall. 
Linear regression analysis was applied to phantom data at the physiologic T1 
and T2, also using appropriate TE and TR values in order to determine the 
lowest concentration of iron yielding a significant signal change. The 
corresponding number (estimated) of iron particles that this represents per voxel 
will be calculated to derive an estimate of the number of macrophages required 
to generate this amount of iron oxide uptake. 
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Figure 26: Effect of voxel size on signal-iron concentration relationship. 
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Macrophage Model 
Frozen cells (J774A.1) were acquired from American Type Culture Collection 
(ATTC) and reconstituted in 75cm2 cell culture flasks in DMEM with 10% FBS 
and 1% Penicillin - Streptomycin Solution. Cells were grown to 75% confluence 
over a period of 3-4 days. Medium was changed daily. 
 
  Figures 27-30 are 40x digital micrographs of macrophages cultured for 24 hours 
at an initial concentration of approximately 5000 cells per slide chamber in 
DMEM with 10% FBS. Cells were then incubated at 37oC in a 5% carbon dioxide 
atmosphere. The medium was then removed, washed with PBS to remove any 
non-adherent (non-viable) cells and replaced with fresh medium containing 0.0 
(Fig 27), 1.0 (Fig 28), 10 (Fig 29) and 100 (Fig 30) µL of stock Feridex in 1 ml 
standard DMEM medium with 10% FBS. After 4 hours medium was removed, 
cells washed 3x with 1X PBS (4ºC) and fixed with 3% glutaraldehyde overnight. 
Cells were stained with Acridine orange for cytoplasm and nucleus and counter-
stained with Prussian blue for iron. 
 
The dose dependent increase in cytoplasmic iron can be observed. Arrows in 
figure 28 indicate small accumulations. Color based analysis available on the 
digital microscope was used to integrate the area of iron (see example in figure 
13) and relate it to the area of the cytoplasm and nucleus. Automated cell 
counting will calculate the average absolute area of iron in each cell.  This was 
used to determine differences in iron uptake in treated versus control 
macrophage cell groups. 
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 Control
 
Figure 27: J774 macrophages stained with Acridine Orange and Prussian Blue. 
Control culture without iron particles.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1µ L Feridex
Figure 28: J774 macrophages incubated for 4 hours with 1µL/800µL then 
stained with Acridine Orange and Prussian Blue.  
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 10µ L Feridex
Figure 29: J774 macrophages incubated for 4 hours with 10.0 mL/800 mL then 
stained with Acridine Orange and Prussian Blue. Regions of cytoplasmic iron is 
present. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100µ L Feridex
Figure 30:J774 macrophages incubated with 100µL Feridex. Cytoplasmic space 
is filled with iron particles. 
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Validation of Method used to Determine Macrophage Cell Density 
Cell density was automatically estimated by creating a ratio between the area in 
µm 2 of the orange band of the color spectrum determined to be specific for 
macrophage nuclear staining using Acridine orange, to the total area scanned by 
the ChromaVision system. Validation was performed using Scion Image 4.0.2 a 
PC version of the NIH Image analysis program. In sub-regions containing 
between 50-300 cells (figure 31), the orange area/total are ratio was compared to 
direct semi-automated cell counting (figure 32). Specifically, images were filtered 
using an edge enhancement filter (Sobel), then converted to binary data using a 
manually applied threshold. A cell counting program within Scion software 
version 4.0.2 (Scion Corp, www.scioncorp.com) was then applied (Figure 32).  
 
Manual editing was applied to correct for touching cells being undercounted or 
non-cell material resulting in an over-count. The images below are examples of 
the raw data (figure 31) and the Scion processed (figure 32) and numbered cells. 
The nuclear orange area/total area for all slides was 3.18+3.59%.  
 
 
Figure 32:Processed image with cell density 
calculated using SCION Image software. 
 
 
Figure 31: Sub-region of cells used for validation 
of automated cell density. 
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Linear Regression of automated cell density versus manual cell count 
 
Cell Count = -33.303 + (11.378 * Orange Ratio (%))  
 
N  = 10.000  
 
R = 0.992 Rsqr = 0.984 Adj Rsqr = 0.982 
 
Standard Error of Estimate = 9.464  
 
    Coefficient Std. Error t    P     
Constant  -33.303 8.083  -4.120  0.003    
Orange Ratio (%) 11.378 0.517  22.017 <0.001  
  
 
Analysis of Variance: 
    DF   SS    MS     F     P   
Regression 1 43413.517 43413.517 484.740 <0.001  
Residual 8 716.483 89.560    
Total  9 44130.000 4903.333    
 
Normality Test:  Passed (P = 0.823) 
Constant Variance Test: Passed (P = 0.081) 
Power of performed test with alpha = 0.050: 1.000 
 
 
It can be seen from the slope of the regression equation (Coefficient for Orange 
ratio) that the Orange Area Ratio as measures by the ChromaVision system 
provided an underestimation of the cell density compared to direct cell counting. 
The overall relation ship was quite linear (figure 33, R2 = 0.98) and thus permits 
use of the regression equation as a correction factor to accurately predict actual 
cell density.  
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Figure 33: Regression analysis of semi-automated cell counting (SCION Image) versus fully 
automated area based cell density calculation (ChromaVision). 
 
Validation of Macrophage Uptake of Iron Nanoparticles 
Iron uptake was determined by calculating the ratio of area (number of pixels) of 
the blue part of the full color spectrum determined to be associated with Prussian 
blue staining of iron particles inside macrophages to total area analyzed. Results 
in treatment wells were compared to control wells incubated with the same 
concentration of Feridex. Results were expressed as a percent increase or 
decrease to control. Validation included 1. Determination of the level of 
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“background” blue. This was the average blue area ratio in wells not treated with 
Feridex. 2. The relationship between iron concentration and blue area ratio over 
the tested iron range, and at multiple points over a lower concentration range 
was determined using linear regression analysis. Due to the particle size, direct 
comparison between blue area ratio and the number of particles is not possible 
as with cell number to orange area ratio. The regression analysis disclosed an 
underestimation of iron uptake (as measured by blue area ratio) as the iron 
concentration increased. This could be caused by a number of factors. First, the 
amount of iron taken up by cells may not be an exact measure of the amount of 
iron internalized. While it is known that uptake increases with increasing 
concentration, trans-membrane routes of internalization may become saturated 
resulting in the observed non-linearity. Secondly, the ChromaVision system is a 
2D measure of 3D cells and cell iron. Iron particles located behind the cell 
nucleus or out of the focal plane could be undercounted or missed entirely. It is 
for these reasons that relative comparisons between control and treatment wells 
with the same iron concentration rather than absolute internal cell iron were 
used. 
 
Uptake Characteristics in Untreated Cells 
Untreated cells from all slides were pooled to permit analysis of SPIO dose 
uptake relationships. Figure 34 compares the calculated area associated with  
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Figure 34:Plot of concentration of administered iron versus calculated "Blue" area. 
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 Prussian Blue SPIO for control and the 3 SPIO doses. In the 22 pooled samples, 
the mean blue area ratio (blue area in µm2/total sampled area in µm2 x 100) was 
19.4+7.6% at a 100 µL (1.12mg/ml) dose, 9.9 +5.6% for a 10 µL (112.0 µg/ml) 
dose, 3.1+5.5% at a dose of 1.0 µL (11.2 µg/ml) and 0.1+0.4% in the control 
wells. This last value represents the background error associated with the 
analysis method and will be covered in more detail in the “Validation” section. 
There was a strong relationship between dose and area ratio. Linear regression 
analysis was performed after performing a log transform of both the SPIO 
concentration and the area ratio values. Figure 35 is a plot of this relationship. 
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Figure 35: Iron (SPIO) concentration versus ChromaVision derived "Blue " area after log 
transform. 
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 The r2 value of this relationship is 0.92 and the regression equation: log (Iron 
Concentration) = -6.157 + (3.681 * log (Blue Area)). It can be seen from the slope 
that at higher SPIO concentrations the uptake is not in proportion to dose. This is 
also evident from the calculated (Area Ratio / SPIO concentration) ratio which 
falls from 30.9 at 1 µL to 9.8 at 10 µL to 1.9 at the highest SPIO concentration 
(100 µL). This is most likely due to saturation of endocytotic pathways. However, 
nonlinear performance of the digital image analysis system may also contribute 
to this effect. To better understand this relationship a group of cells were 
incubated with 2,4,6,8,10,12,14 and 16 µL of stock Feridex. The relationship 
(Figure 36) was similar to that observed over the 0-100 µL SPIO range. Again the 
area ratio did not increase at the same rate as the SPIO concentration. The r2 
value derived from linear regression analysis was 0.99 and the regression 
equation: Iron Concentration = -3.529 + (0.112 * Blue Area ). 
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Figure 36: Iron concentration-Blue area relationship over limited "low-dose" range. 
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Time-Uptake Relationship 
The time –uptake relationship was determined in macrophages incubated with 
10µL stock Feridex solution. Cells were fixed after 5, 10, 60, 240 360 and 480 
minutes of incubation. Background from untreated cells not exposed to SPIO was 
determined from a group of 10 samples to be 0.448+0.285 (area ratio). The area 
ratio measured at 5 minutes was 0.843+0.003 which was significantly greater 
than background (p=0.028, 2-tailed t-test). The area ratio peaked at 240 minutes. 
Uptake at 240, 360 and 480 minutes were not significantly different (p=NS, 
ANOVA). Therefore all uptake measurements were calculated after incubation 
with SPIO after 240 minutes. Figure 37 shows examples images of progressive 
SPIO uptake over a 4-hour period. 
Figure 37: Examples of iron uptake after 10 µL Feridex administration. ( 5 min top left, 10 min top 
right, 1 hour bottom left, 4 hours bottom right). Progressive increase in cytoplasmic iron can be 
seen. 
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      Figure 38: Plot of time-uptake relationship for cells incubated with 10 µL Feridex. 
Figure 38 shows the time course of macrophage uptake of SPIO. While there 
was a statistically significant uptake as early as 5 minutes after SPIO 
administration, practically, it can be seen that substantial uptake does not occur 
until after 4-hours of incubation. In that these data were based on a small sample 
at a single dose, a more extensive evaluation looking at multiple SPIO 
concentrations at multiple times was undertaken. 
 
Effect of Iron Oxide Concentration on Time-Uptake Relationship 
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Figure 39: Effect of administered iron concentration on time-uptake relationship. 
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In a separate set of experiments a complete matrix of Time (5 min, 10 min, 60 
and 240 min) x SPIO Dose (1.0 µL/ml, 10 µL.ml and 100 µL/ml) was performed in 
triplicate from the same cell culture, at the same seeding density. 2-way ANOVA 
was performed to evaluate the data.  
 
Two Way Analysis of Variance (variables: Iron Dose and Time) 
 
Source of 
Variation 
 DF   SS   MS    F    P  
Time (min) 3 7139691.639 2379897.213 30.014 <0.001 
Dose 2 859526.056 429763.028 5.420 0.011 
Time (min) 
x Dose 
6 2248937.278 374822.880 4.727 0.003 
Residual 24 1903021.333 79292.556   
Total 35 12151176.306 347176.466   
    
There was no significant uptake at 5 or 10 minutes (not significantly different from 
background blue measured in wells stained with Prussian blue in the absence of 
iron oxide particles). By 1 hour blue area was significantly different from 
background for all iron concentration (figure 39). Further, blue area was greater 
at the 100µL dose versus both 1.0 and 10.0 µL levels. This interaction between 
dose and uptake is one that will be consistently seen with the treatment 
experiments. The full output of the 2-way ANOVA including interactions between 
dose and uptake are listed in Appendix A1. 
 
Effect of Treatment on Macrophage Cell Density 
The quantification of macrophage uptake of iron oxide particles is performed by 
comparing the “blue area” after Prussian blue staining between control and 
treatment. This method is valid only if cell density is similar between control and 
treatment or if statistical differences in cell density are taken into account and 
used to scale blue area to cell density. The table below presents the results of 
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analysis of 3 sub-regions in control and treatment in wells in which iron oxide 
particles were not added. The ratio of orange area to region of interest area x100 
was determined and a 2-tailed paired t-test performed. When there was not 
difference between control and treatment cell density, 2-way analysis of variance 
was performed using the original data. When a difference (P<0.05) was 
observed, the treatment blue area was scaled to compensate for either an 
increase or decrease in treatment cell density. Two-way ANOVA was performed 
on the scaled data and raw data for comparison. 
 
Table 7: Analysis of cell density in control versus treatment groups. 
Treatment Control 
Area-Ratio 
Treatment 
Area-Ratio 
t-test 
P-value 
Scale Factor 
FBS 0.457+0.184 0.481+0.280 0.056 none 
Mannan 1.069+1.127 0.230+0.296 0.281 none 
ACEI 0.01mM 0.410+0.362 0.544+0.404 0.157 None 
ACEI 0.1 mM 2.839+1.227 2.933+2.553 0.310 None 
ACEI 1.0mM 3.286+3.351 5.010+7.391 0.233 none 
IL-4 10 ng 26.181+4.169 24.228+3.910 0.751 none 
IL-4 20 ng 19.921+2.03 22.057+1.888 0.551 none 
IL-4 40 ng 23.189+1.102 18.979+5.328 0.310 none 
IFN-g 10 U 0.200+0.219 0.260+0.251 0.616 none 
IFN-g 100 U 15.781+2.623 17.701+3.623 0.499 none 
IFN-g 500 U 8.310+3.400 7.417+1.881 0.743 none 
IFN-g 1000U 5.182+2.492 5.133+1.301 0.692 none 
Cytochasin D 18.054+16.136 21.505+33.285 0.879 none 
HMG 1mM 5.723+4.36 5.462+4.074 0.943 none 
HMG 17.5 mM 10.392+2.935 6.131+1.019 0.033 1.69 
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Effect of the Presence or Absence of Serum Proteins on SPIO 
Uptake 
 
 
Source of 
Variation 
 DF   SS   MS    F    P  
[iron] 3 3133692587.125 1044564195.708 481.432 <0.001 
FBS 1 97433310.375 97433310.375 44.906 <0.001 
[iron] x 
FBS 
3 317465364.458 105821788.153 48.772 <0.001 
Residual 16 34715270.000 2169704.375   
Total 23 3583306531.958 155795936.172   
  
 
Opsonification is known to be one mechanism by which particulate material is 
endocytosed by macrophages. Data from the present study showed SPIO uptake 
(pooled across iron dose) in macrophages incubated in the presence of 10% 
FBS to be 1.6 times greater than in cells incubated without FBS. Bogdanov et 
al.49 using a similar dextran coated iron oxide particle showed an even greater 
difference. Uptake of particles opsonized  by incubation with undiluted serum for 
1 hour showed a 6-fold greater uptake in macrophages than in untreated 
particles. It is likely that incubation in pure serum achieved a higher number of 
opsonized particles than the use of 10% serum in the present study. It should 
also be noted that Bogdanov et al.42 use gamma counting of I-125 labeled 
particles to quantify macrophage uptake. It is not known how results using this 
method compare to the image based method of the present study. In a separate 
publication by the same group, (Bogdanov et al.69 ), the authors presumed that 
iron particles opsonized to plasma proteins enter the macrophage via Fc- or CR- 
receptors. While this is certainly plausible based on the known selectivity of these 
2 receptors, some small portion of the increase in uptake may be the result of the 
25% increase in particle size (Bodanov et al.) resulting from binding to plasma 
proteins. In neither the present study nor that by Bogdanov was SPIO uptake 
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completely eliminated. Thus, while opsonification reduces uptake, other 
endocytotic pathways must exist. 
 
 
 
Effect of Cytochalasin B on Iron Uptake 
 
Source of 
Variation 
 DF   SS   MS    F    P  
[iron] 3 4642205912.167 1547401970.722 117.310 <0.001 
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Figure 40: Effect of presence or absence of serum proteins on macrophage uptake of SPIO 
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CYTO 
1mcg/ml 
1 53133504.167 53133504.167 4.028 0.062 
[iron] x 
CYTO 
1mcg/ml 
3 191873468.167 63957822.722 4.849 0.014 
Residual 16 211051657.333 13190728.583   
Total 23 5098264541.833 221663675.732   
    
  
There was a trend (P=0.062) that did not reach a significant level for treatment 
with cytochalasin B to reduce SPIO uptake. Based on the results from Pratten et 
al, that compared change in macrophage uptake of various size particles, only 
100 nm latex particles and the soluble macromolecule polyvinylpyrrolidone (7 x 
106 Da)  were unaffected by cytochalasin B treatment. They showed that 300 nm 
particles displayed 69% of control uptake, uptake further dropped to 68% and 
59% of control for 600 nm and 1100 nm latex particles respectively. It was 
determined that Feridex particles, aggregate in groups of particles (Jacobs40). 
Pratten et al further report that phagocytosis but not pinocytosis is substantially 
inhibited with 1 µg/ml cytochalasin B. Results from the present study might 
indicate that trans-membrane SPIO internalization occurs more by pinocytosis of 
individual or small groups of iron particles, or via receptor mediated pathways 
rather than phagocytosis of the entire aggregate. Endocytosis by means of 
adsorptive piocytosis, or receptor mediated means requiring interaction between 
individual particles and the cell surface prior to internalization would be 
consistent with the results observed in the present study. Complete output of the 
2-way ANOVA is presented in appendix A3. 
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Effect of Blocking Mannose Receptors with Mannan 
 
Source of 
Variation 
 DF   SS   MS    F    P  
Mannan 
Block 
1 5422602.667 5422602.667 1.888 0.188 
[iron] 3 178080852.333 59360284.111 20.663 <0.001 
Mannan 
Block x 
[iron] 
3 21179777.667 7059925.889 2.458 0.100 
Residual 16 45964028.667 2872751.792   
Total 23 250647261.333 10897707.014   
    
 
Addition of 1 mg/ml of mannan had no significant effect on macrophage 
internalization of Feridex at any tested concentration indicating that the mannose 
receptor does not play a significant role in endocytosis of the study particle even 
though it has a glucose polymer as a coating. Mannose receptors (MR) 
recognizes the patterns of carbohydrates that decorate the surfaces and cell 
walls of infectious agents. Previous studies have shown the MR to be involved in 
endocytosis of a wide range of materials. Montaner et al.47 showed that horse 
radish peroxidase, generally used as a marker of fluid phase pinocytosis, also 
used the MR receptor pathway as evidenced by the effect of mannan block. Le 
Cabec et al.73 showed that phagocytosis of the 6 µm polysaccharide zymosan 
particle was substantially inhibited after mannan treatment. The range of these 2 
previous materials spans that of Feridex and excludes particle size as the factor 
inhibiting mannose receptor-mediated uptake. 
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Effect of Interleuken-4 on Macrophage Uptake of Iron Oxide 
a. IL-4 at 10 ng/ml 
 
 
Source of 
Variation 
 DF   SS   MS    F    P  
IL-4 (10 
ng/ml) 
1 20276816.667 20276816.667 1.692 0.212 
[iron] 3 4540930168.833 1513643389.611 126.318 <0.001 
IL-4 (10 
ng/ml) x 
[iron] 
3 145048807.667 48349602.556 4.035 0.026 
Residual 16 191724197.333 11982762.333   
Total 23 4897979990.500 212955651.761   
 
 
b. IL-4 (20 ng/ml) 
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
IL-4 (20 
ng/ml) 
1 93750.000 93750.000 0.00461 0.947 
[iron] 3 4781933262.333 1593977754.111 78.450 <0.001 
IL-4 (20 
ng/ml) x 
[iron] 
3 5172533.000 1724177.667 0.0849 0.967 
Residual 16 325095190.000 20318449.375   
Total 23 5112294735.333 222273684.145   
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c. IL-4 (40 ng/ml) 
 
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
IL-4 (40 
ng/ml) 
1 114821876.042 114821876.042 5.514 0.032 
[iron] 3 5574749793.125 1858249931.042 89.239 <0.001 
IL-4 (40 
ng/ml) x 
[iron] 
3 131018250.125 43672750.042 2.097 0.141 
Residual 16 333171619.333 20823226.208   
Total 23 6153761538.625 267554849.505   
    
 
Iron Area Per Total Area (%) 
Control   Treatment 
100 µL Iron: 40.29+11.17   54.94+11.11 
10 µL Iron: 10.42+3.16   17.23+2.58 
1 mL Iron 0.79+0.61   1.42+0.44 
 
Interlueken-4 is produced by Th2 T-lymphocytes and its effect on macrophage 
activity is dependent on the presence of other cytokines. In the presence of IL-
10, IL-4 acts in an immuno-regulatory manner to decrease the activity of 
activated macrophages. By itself, IL-4 has been shown to induce Mannose 
receptor expression and endocytosis in macrophages and induce an alternative 
form of macrophage activation74 (Gordon, http://dunn1.path.ox.ac.uk/-
cholt/sgCytoMacro.html74). In the present study IL-4 was studied at 10, 20 and 40 
ng/ml. No effect on SPIO uptake was measured at the 2 lower concentrations. At 
40 ng/ml there was a significant increase in uptake of SPIO (10198 µm2 blue 
versus 14573µm2) which expressed as percent blue of total area equates to 
12.9+1.20% and 18.3+1.73% for control and IL-4 (40ng/ml) respectively (figure 
41). Two-way ANOVA indicated that the treatment effect was similar at the 3 
tested iron particle concentrations. There have been no previous studies 
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investigating the effect of IL-4 treatment on macrophage uptake of iron oxide 
particles. Montaner et al.47used horseradish peroxidase (HRP) and to probe the 
effects of IL-4 on macrophage pinocytosis and mannose receptor endocytosis. 
They showed that treatment with 20 ng/ml of IL-4 resulted in a 2.8 fold increase 
in non-mannose receptor uptake and a 6-fold increase in mannose receptor 
mediated endocytosis. While the direction of change reported by Montaner et 
al.40 is the same as that reported in the present study, there are a number of 
factors that may explain the difference in the magnitude of effect observed after 
IL-4 treatment. In the Montaner study. Cells were treated with IL-4 for 6 days 
prior to measuring cell uptake, while the present study limited treatment to 24 
hours. IL-mediates uptake on a number of levels including the increase in density 
of tubular vesicles underneath the plasma membrane and increase gene 
Figure 41: Effect of the cytokine IL-4 (40 ng/ml) on macrophage uptake of SPIO 
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expression of both transferring and mannose receptors. The time required for 
these separate events may result in less upregulation of pinocytosis and 
endocytosis after 1 versus 6 days of IL-4 treatment. The material tested by 
Montaner (HRP) showed significant macrophage uptake via the mannose 
receptor pathway. The present study showed no significant reduction in uptake 
when the mannose receptor was blocked with mannan. Finally, the Montaner  
study used primary human macrophages incubated with human serum. It is 
possible that these macrophages respond to a greater degree than murine 
macrophages (J774). In a study by Swanson et al75 they showed that HRP itself 
stimulates pinocytosis and may have resulted in an overestimation of the direct 
effect of IL-4 by Montaner et al.  
 
 
Effect of Human Interferon Gamma on Macrophage Uptake of 
Iron Oxide 
a. IFN-γ at 10 U/ml 
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
IFN-γ 
(10u/ml) 
1 3711493.500 3711493.500 0.346 0.565 
[iron] 3 4715548409.500 1571849469.833 146.523 <0.001 
IFN-γ 
(10u/ml) x 
[iron] 
3 1652630.833 550876.944 0.0514 0.984 
Residual 16 171642074.667 10727629.667   
Total 23 4892554608.500 212719765.587   
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b. IFN-γ at 100U/ml 
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
IFN-γ 
(100u/ml) 
1 2335008.167 2335008.167 0.290 0.598 
[iron] 3 6917369859.500 2305789953.167 286.242 <0.001 
IFN-γ 
(100u/ml) 
x [iron] 
3 246260960.167 82086986.722 10.190 <0.001 
Residual 16 128886100.000 8055381.250   
Total 23 7294851927.833 317167475.123   
    
  
 
b. IFN-γ at 500 U/ml   
 
Two Way Analysis of Variance 
 
Source of 
Variation 
 DF   SS   MS    F    P  
IFN-γ 
(500u/ml) 
1 4428.167 4428.167 0.000340 0.986 
[iron] 3 3562854979.333 1187618326.444 91.275 <0.001 
IFN-γ 
(500u/ml) 
x [iron] 
3 17911468.500 5970489.500 0.459 0.715 
Residual 16 208182604.000 13011412.750   
Total 23 3788953480.000 164737107.826   
   
 
c. IFN-γ at 1000U/ml 
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
IFN-γ 1 91057312.667 91057312.667 4.726 0.045 
[iron] 3 2217676090.333 739225363.444 38.366 <0.001 
IFN-γ x 
[iron] 
3 181412470.333 60470823.444 3.138 0.055 
Residual 16 308285008.000 19267813.000   
Total 23 2798430881.333 121670907.884   
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 Figure 42: Effect of high dose (1000U/ml) IFN-γ on macrophage uptake of SPIO 
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Interferon-γ (IFN-γ), is a pleiotropic cytokine widely involved in the regulation of 
both innate and adaptive immune responses. The major biological activities of 
IFN-γ include antiviral and antiproliferative properties, macrophage activation, 
control of apoptosis and promotion of antigen processing, presentation and T 
helper type 1 (TH1) differentiation.76 The present study did not show any effect of 
IFN-γ on SPIO uptake over physiological and moderately elevated levels (10 
ng/ml, 100 ng/ml and 500 ng/ml) of this cytokine. However at high dose (1000U) 
substantially increased SPIO uptake was observed (figure 42). This is the first 
study to evaluate the effect of IFN-γ on SPIO uptake. Previous studies looking at 
the effect of IFN-γ on macrophage function have shown it (20ng/ml) to reduce 
both pinocytosis and mannose receptor-mediated endocytosis of HRP in vitro.47  
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Stopeck et al.77 reported that  this low dose IFN-γ had no effect on LDL receptor 
activity. Taken together these reports fit with the data from the present study 
where IFN-γ showed no effect on SPIO internalization at comparable cytokine 
concentrations which would tend exclude a mannose receptor pathway (as did 
the mannan block data). Secondly, the lack of effect of IFN-γ (10-500 U/ml)  on 
LDL receptor activity would permit the continued consideration of the LDL 
receptor pathway as a potential route for SPIO entry. The effect of high IFN-g 
concentration on SPIO uptake may be the result (but not proven in the present 
study) of secondary biomolecules. For example Inagaki et al.78 reported that 
human macrophage cells produced monocyte chemoattractant protein-1 (MCP-1) 
increasingly as IFN-γ concentration was increased. MCP-1 is know to directly 
activate macrophages79 and may explain the increased SPIO endocytosis in the 
present study. Finally, Schulze et al. 80 reported  that the SPIO was efficiently 
endocytosed in C6 cells at concentrations of 4.0x10-10 M Fe, which the authors 
concluded was “several orders of magnitude below which significant uptake by 
fluid phase pinocytosis would occur.” 
 
Effect of Angiotensin Converting Enzyme (ACE) Inhibition on 
Macrophage Uptake of Iron Oxide 
 
a. Captopril at 0.01 mM 
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
CAPT 
0.01mM 
1 1397320.042 1397320.042 0.0919 0.766 
[iron] 3 4773544524.458 1591181508.153 104.693 <0.001 
CAPT 
0.01mM x 
[iron] 
3 1533378.125 511126.042 0.0336 0.991 
Residual 16 243176560.000 15198535.000   
Total 23 5019651782.625 218245729.679   
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b. Captopril at 0.1 mM   
 
Two Way Analysis of Variance Wednesday, July 12, 2000, 19:15:23 
 
Source of 
Variation 
 DF   SS   MS    F    P  
CAPT 
0.1mM 
1 1443541.500 1443541.500 0.373 0.550 
[iron] 3 3468539248.833 1156179749.611 298.661 <0.001 
CAPT 
0.1mM x 
[iron] 
3 3719204.167 1239734.722 0.320 0.811 
Residual 16 61939300.000 3871206.250   
Total 23 3535641294.500 153723534.543   
   
 
c. Captopril 1.0 mM  
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
CAPT 
1.0mM 
1 1458294.000 1458294.000 0.102 0.753 
[iron] 3 5002019394.167 1667339798.056 117.156 <0.001 
CAPT 
1.0mM x 
[iron] 
3 7517576.333 2505858.778 0.176 0.911 
Residual 16 227707774.000 14231735.875   
Total 23 5238703038.500 227769697.326   
   
Captopril is classified as an ACE inhibitor. ACE inhibitors block the body's 
production of angiotensin-converting enzymes (ACE), a chemical needed by the 
body to make angiotensin II, a chemical that increases blood pressure by 
narrowing arteries. This process leaves blood vessels more relaxed, which 
decreases blood pressure and increases the flow of blood and oxygen to the 
heart. Captopril is primarily used for treatment of high blood pressure. However 
its effect on macrophage function and effect on atherosclerotic progression has 
been established. In the present study, treatment with 0.01 mM, 0.1 mM or 1.0 
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mM Captopril effected neither cell density or SPIO uptake. Keider et al.81 showed 
that Ang-II possesses additional atherogenic properties such as increasing the 
activity of the macrophage oxidized LDL receptors. Hayek et al.82showed that 
ACE treatment significantly reduced oxLDL uptake by macrophages.  The 
present study has shown a significant reduction of SPIO uptake in HMG CoA 
reductase inhibitor treated cells. These data were used to implicate a role for the 
macrophage LDL receptor as an endocytotic SPIO uptake. However the data by 
Keider et. al and Hayek et al. do not necessarily contradict this hypothesis. In 
both of these studies, the mode of action of ACE inhibition was not directly on the 
macrophage receptor but rather by way of reducing elevated angiotensin II.  It 
has been well validated that angiotensin II, particularly when elevated, stimulates 
lipid accumulation by increasing oxLDL  receptor density (Keider et al.). It can 
also increase lipid peroxidation, thus increasing the concentration of lipids 
endocytosed via the non-concentration regulated oxLDL receptor.83  The medium 
used in this study, DMEM is free from angiotensin II however, the FBS likely 
contains at least low levels. Thus, the lack of change in macrophage uptake of 
SPIO, indicates that none of the direct effects of ACE inhibition alter the 
pathways used by macrophages to internalize iron particles. Specifically, The 
known effect of ACE inhibitors on angiotensin II do not significantly alter lipid 
other receptors, or other modes of SPIO internalization.  
 
Effect of HMG CoA Reductase Inhibition (Mevinolin) on Macrophage Uptake 
of Iron Oxide 
 
a. Mevinolin (1.0 µM) 
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
HMG 
1.0mcM 
1 132337977.042 132337977.042 11.208 0.004 
[iron] 3 3500330496.458 1166776832.153 98.813 <0.001 
HMG 
1.0mcM x 
3 213200698.458 71066899.486 6.019 0.006 
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[iron] 
Residual 16 188927352.000 11807959.500   
Total 23 4034796523.958 175425935.824   
  
 
 
 
b. Mevinolin (17.5 µM) 
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
HMG 1 283064622.042 283064622.042 26.913 <0.001 
[iron2] 3 2449715493.458 816571831.153 77.637 <0.001 
Figure 43: Effect of 1.0 µM mevinolin on macrophage uptake of SPIO 
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HMG x 
[iron2] 
3 496210450.792 165403483.597 15.726 <0.001 
Residual 16 168285499.333 10517843.708   
Total 23 3397276065.625 147707655.027   
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Figure 44: Effect of 17.5 µM mevinolin on macrophage uptake 
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c. Mevinolin at 17.5 µM Corrected 
  
 (Treatment area multiplied by 1.69 to account for reduced cell density ) 
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
HMG 1 118368107.011 118368107.011 6.623 0.020 
[iron2] 3 3471907563.896 1157302521.299 64.753 <0.001 
HMG x 
[iron2] 
3 170484041.790 56828013.930 3.180 0.053 
Residual 16 285963005.284 17872687.830   
Total 23 4046722717.981 175944465.999   
    
 
Two effects were seen in macrophages treated with the HMG-CoA reductase 
inhibitor mevinolin. At both tested concentrations (1.0 µM and 17.5 µM) SPIO 
uptake was significantly diminished. At the higher HMG concentration there was 
also observed a lower cell density compared to control (table 7). The 
antiproliferative effect of statins has been well documented. Masanori et al 
showed a dose dependent reduction in the number of macrophage cells using 
the HMG-CoA inhibitor cerivastatin. Ten days of incubation of cells with as little 
as 0.01 mM of this agent reduced cell number compared to control. As in the 
present study, cell density was determined by comparison of treated to untreated 
cells. Thus the degree to which this difference represents anti-proliferative versus 
cell death could not be ascertained. A similar effect was seen by Sakai et al.84 in 
macrophages stimulated to proliferate by addition of oxLDL.  The present study 
did not observe a difference between control and HMG (1.0 µM) cells. It should 
be noted that Masanori treated cells for ten days prior to cell counting while the 
present study treated cells for 24 hours.  However, incubation of cells with 17.5 
µM HMG resulted in a 40% cell density compared to control.  
 
This is the first study to document the effect of HMG treatment on macrophage 
uptake of iron oxide particles. Pooled across iron concentration 1.0 µM of 
Mevinolin resulted in a 34% decrease in SPIO uptake (figure 43), while 17.1mM 
 92
statin reduced SPIO uptake 66% (figure 44) prior to correcting for the observed 
reduction in cell density and 42% after correction. 
 
 The effect of statins on macrophage endocytosis of oxidized LDL uptake has 
been well studied. Specifically, regulation the scavenger class of receptors by 
statins may be relevant to the present study.  Zingg et al.85 describe the 5 
classes of scavenger receptors as a diverse group capable of directly binding 
and internalizing fatty acids, cholesterol oxLDL, HDL, LPS and indirectly aiding in 
endocytosis of materials as diverse as collagen, infected erythrocytes, bacteria 
and plastic.  The size, structure and surface properties of Feridex are not 
dissimilar to some of these materials. Lovastatin has been shown to inhibit gene 
expression of the A1 scavenger receptor in human macrophages and thus 
reduce endocytosis of SR-A1 materials.86 . Bellosta et al87 showed a dose related 
inhibition of oxLDL uptake in macrophages treated with Fluvastatin. Uptake 
inhibition ranged from 14% at 0.005µM to 55% at 10.0µM. In a separate study 
the same group88  determine that the HMG effect is not one of general 
downregulation of all endocytotic function by measuring a slight but significant 
increase in native LDL uptake during macrophage treatment with Simvastatin. 
Interpretation of data from the present study in light of previous results warrants 
further study to determine if scavenger receptors represent a significant 
endocytotic route for SPIO particles. 
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Discussion 
 
Effect of Iron-Labeled Cells on MRI Signal Properties 
The present study evaluated the MRI signal properties using a gel phantom 
loaded with increasing concentrations of the test USPIO nanoparticle. Dodd et 
al.89 isolated Fischer 344 rat T cells and incubated them in culture medium with 
USPIO at a concentration of 2 mg Fe/10 x 106 cells. Using electron microscopy 
they confirmed that the dextran-coated USPIO particles were located in the 
phagocytic vacuoles. USPIO containing cells were suspended in gel at 
concentrations of 0.25, 1.0 and 2 x 106 cells/ml. Using higher resolution (50 x 50 
µm) than the present study but similar scan parameters (TR = 1000 msec, TE = 
30 msec) they evaluated the change in MR signal properties at 4.7 T. As in the 
present study overall signal intensity decreased as cell (iron) concentration 
increased. Their data showing that increasing TE resulted in decreased signal at 
the same cell (iron) concentration was in agreement to with data from the present 
study at 1.5T. Thus, it may be concluded that the T2 shortening effect of USPIO 
is similar whether the particles are intra- or extra-cellular.  
 
Clinical Application of Feridex as a Liver Imaging Agent  
The only FDA approved application of the USPIO agent (Feridex) is for detection 
of hepatocellular carcinoma. Administered IV, this agent is cleared from the 
circulation by phagocytosis of the reticuloendothelial system, including the 
Kupffer cells of the liver. It is the very efficient and rapid removal of feridex from 
the circulation which may limit its in vivo application to indirect visualization of 
vascular macrophages. A different product (AMI 7228) has been designed as an 
intravascular contrast agent,  to have a longer circulation time, thus permitting 
grater uptake in vascular macrophages. The application for AMI 7228 is to 
improve blood signal for MR angiographic applications. Most focal liver lesions , 
particularly malignant tumors lack Kupffer cells. Therefore, the loss of signal 
associated with the USPIO particle is not observed in lesions resulting in retained 
high signal and contrast between normal and affected tissue.  
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 In a study by Schultz et al.90 they compared liver MRI using Feridex with CT for 
the detection of either primary or metastatic hepatic lesions in 57 patients. They 
concluded that, in this population , contrast enhanced MRI detected 76% more 
lesions than CT. Additionally, MRI was able to detect smaller lesions. The overall 
sensitivity ( versus pathology in a subgroup of 22 patients) was 86% for MRI and 
58% for CT (P<0.001). Thus by taking advantage of the cell specificity of this iron 
agent, the authors showed a significant improvement in diagnostic accuracy. 
Finally the authors calculated that MR results negated the need for biopsy in 18 
patients and laproscomy in an additional 8. The calculated savings was $1901 
per patient studied. 
 
Potential Effects of Intracellular USPIO on Cell Homeostasis 
Normally iron in serum is present at a concentration between 3-5 µg/ml. and is 
largely bound to transferrin. 91 Transferrin binds with two Fe3+ ions. Diferric 
transferrin binds to cell surface receptors and the transferrin-transferrin receptor 
complex is internalized in clatherin-coated vescicles. The vesicles loose their 
coat, fuse with endosomes and the iron is solubilized in lysosomes. USPIO, as 
has been shown in the present study, likely enter the cell via pinocytosis and 
receptor mediated endocytosis. Once inside the lysosome, the dextran coat is 
lost and it likely continues along the same pathway as native iron.33 
Cellular iron homeostasis is regulated at the level of mRNA translation rather 
than synthesis. Iron regulatory element-binding proteins (IRP’s 1 and 2) change 
conformation based on the cytosolic concentration of iron. When iron 
concentration is high, IRP-1 protein is inactivated and IRP-2 is rapidly degraded. 
This results in down-regulation of transferric-receptor synthesis. In the presence 
of low iron, the mRNA for the transferring receptor is protected from nuclease 
attack, permitting increased receptor mediated iron uptake.  
 
There are a number of mechanisms by which excess cellular iron can produce 
damage. Low molecular weight iron can act as a catalyst in the Fenton reaction 
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to potentiate oxygen toxicity by the generation of a wide range of free radical 
species, including hydroxyl radicals, OH•. For example:  
Fe2+ + H2O2→Fe3+ + OH- + OH• 
Hydroxyl radicals are known to react with a wide range of cellular components 
including the amino acid residues and purine  and pyrimidine bases of DNA, 
membrane lipinds and can  initiate lipid peroxidation. Cells differ in their 
sensitivity to the harmful effects of iron overload. Cells such as liver hepatocytes 
containing a high level of antioxidant protection are less sensitive, while neural 
cells will be more sensitive to iron mediated oxidative stress. Because of their 
role in being able to phagocytose senescent red blood cells, macrophages have 
developed an advanced method to balance cellular iron concentractions.  
The production of NO by macrophages is a major defense mechanism used 
against invading organisms. Legssyer et al. 92 used dextran coated iron particles 
similar to the USPIO used in the present study to evaluate the effect of iron 
loading on the ability of macrophages to respond to infection. Through 
intraperitoneal injections they were able to double the iron content in alveolar 
macrophages. They showed that primary macrophage cultures from this mouse 
model stimulated with IFN-γ for 44 hrs, displayed a significant reduction in NO 
production. These data indicate that macrophages overloaded with iron show a 
diminished capacity to produce NO. It is not clear as to the actual amount of 
increased iron associated with a clinical dose of USPIO. Thus, while there exists 
the potential for iron to affect the immune macrophage response, the dose-
response relationship has not been established. 
 
Future Directions 
The results of this study indicate that macrophage uptake of USPIO is regulated. 
However there are a number of important question beyond the scope of the in 
vitro model used for this study. 
 
Question 1. Can the downregulation observed in “statin” treated cells be 
replicated using an in vivo animal model? 
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 Potential approach: the Watanabe White Hyperlipidemic Rabbit is a well studied 
model for aortic atherosclerosis. While the developed lesions are lipidic in nature 
compared to the complex human lesions, they are rich in macrophages and have 
been used in previous USPIO studies. After approval from the Animal Care and 
Use Committee, I propose to study 4 groups of rabbits using the smaller USPIO 
agent AMI 7228. This material has a longer blood residence time which should 
enhance uptake of arterial macrophages. Group I will serve as a control (no 
statin treatment), group II will be placed on statins at a weight adjusted dose to 
correspond to the human dose of 20 mg/day 1 month prior to imaging. Group III 
will be treated at the same dose for only 2 days prior to imaging and group IV will 
be treated for 1 week  at the same dose with statin therapy withdrawn 3 week 
prior to imaging. All animals will be the same age at initiation of the study and will 
be on identical high cholesterol diets. This design will address in vivo time 
required for induction of effect (if observed), the carry-over effect of treatment. 
 
Question 2a. Does the distribution of USPIO within human carotid plaque 
correspond to regions associated with plaque instability based on morphology 
and inflammatory components? 
Question 2b. Does statin treatment reduce USPIO concentration and is there an 
association between USPIO uptake and the presence of histological and 
morphological features of plaque instability? 
 
Potential approach: Human carotid endarterectomy is still a common clinical 
treatment for carotid stenoses. This procedure provides a means of performing 
human in vivo imaging with nearly immediate post-imaging histological 
verification. After approval from the Human Investigation Committee, enrolled 
patients will be administered a clinically approved dose of Feridex or AMI 7228 (if 
FDA approved) and imaged the following day using a 3D high resolution T2 
weighted sequence with planes oriented to cut the carotid artery in cross section 
from 2 cm above, to 2 cm below the carotid bifurcation.  Excised specimens will 
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be processed and stained for iron, macrophages, as well as other inflammatory 
and structural components. Macrophage and USPIO concentration will be 
estimated from histology and compared with MRI. After comparison, results from 
patients on statin at the time of imaging (duration limits to be established) will be 
compared to untreated “controls”.   
 
 
Conclusions 
As is often the case in such studies, the resultant data raise as many new 
questions as they do answer. However, a number of conclusions may be drawn 
in the context of the experimental model. The major hypothesis that uptake of 
SPIO particles by macrophages is regulated by both endogenous and exogenous 
factors, is supported by the 3 treatment groups that resulted in modulated  
USPIO internalization. Specifically, the presence of serum proteins (FBS) 
appears to be involved in a receptor-mediated pathway. The study by Bogdanov 
et al.49 speculated, but did not prove, that Fc- and/or CR-receptors were involved. 
Importantly, their results showing lack of enhanced uptake in C6 glioma cells  
supports their conclusion that enhanced pinocytosis did not explain the increased 
uptake.  
 
Interleukin-4 is produced by Th2 T-lymphocytes and its effects can oppose those 
of IFN-gamma, which is why these two cytokines were chosen for the present 
study. IL-4 induces Mannose receptor expression and endocytosis in 
macrophages. In atherosclerotic lesions IL-4 inhibits smooth muscle cell 
proliferation and stimulates the production of MMP’s. The enhanced USPIO 
internalization seen in the present study, in the presence of   IL-4 (40 ng/ml), 
does not specifically implicate an internalization pathway, but supports the idea 
that a receptor-mediated pathway, rather than accelerated pinocytosis is 
responsible for the increased USPIO uptake.93  This is further supported by the 
effect of cell treatment with mevinolin.  In addition to its anti-proliferative effect on 
macrophages, Umetani et al.59 showed that it directly down-regulated expression 
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of  type-1 scavenger receptor mRNA. Again this indirectly supports receptor-
mediated endocytosis of USPIO. 
 
It is important to integrate the limitations of the present study into any 
conclusions. The most obvious limitation is the experimental model. Cells were 
exposed to a single treatment agent at a time. It is well appreciated that actual 
atherosclerotic lesion contain a diverse group of biomolecules that often act in 
opposing directions. Thus, the effects seen in the present study only indicate the 
potential for the tested materials to modulate USPIO uptake. Further, factors 
such as cell density, and other macrophage cell lines could have a significant 
effect on macrophage phagocytic capacity.  
 
 If these results are reproduced in vivo, there are several implications for clinical 
imaging studies. Due to the widespread use of statins in cardiovascular disease 
patients, it is likely that many USPIO enhanced MRI studies will be performed 
and interpreted with this drug present. Lack of USPIO-associated signal loss in 
the vascular wall will not necessarily prove the absence of inflammatory cells 
such as macrophages. Further, the present data do not provide any information 
the effect of withdrawing statin therapy on macrophage uptake in either the short-
term (life-span of the exposed macrophage) or long term, when previously statin-
unexposed cells migrate into the vessel wall.  Based on in vivo studies, USPIO 
enhanced MRI may not only be able to indirectly detect vascular inflammation but 
may be able to assess the effect of anti-inflammatory drug therapy. 
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Appendices 
 
A1. Dose-Time Analysis 
Two Way Analysis of Variance  
Source of 
Variation 
 DF   SS   MS    F    P  
Time (min) 3 7139691.639 2379897.213 30.014 <0.001 
Dose 2 859526.056 429763.028 5.420 0.011 
Time (min) 
x Dose 
6 2248937.278 374822.880 4.727 0.003 
Residual 24 1903021.333 79292.556   
Total 35 12151176.306 347176.466   
    
The difference in the mean values among the different levels of Time (min) is 
greater than would be expected by chance after allowing for effects of differences 
in Dose.  There is a statistically significant difference (P = <0.001).  To isolate 
which group(s) differ from the others use a multiple comparison procedure. 
 
The difference in the mean values among the different levels of Dose is greater 
than would be expected by chance after allowing for effects of differences in 
Time (min).  There is a statistically significant difference (P = 0.011).  To isolate 
which group(s) differ from the others use a multiple comparison procedure. 
 
The effect of different levels of Time (min) depends on what level of Dose is 
present.  There is a statistically significant interaction between Time (min) and 
Dose.  (P = 0.003) 
 
Power of performed test with alpha = 0.0500:  for Time (min) : 1.000 
Power of performed test with alpha = 0.0500:  for Dose : 0.707 
Power of performed test with alpha = 0.0500:  for Time (min) x Dose : 0.903 
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Least square means for Time (min) :  
Group  Mean  
240.000 1084.222  
60.000 194.556  
10.000 6.111  
5.000  11.667  
Std Err of LS Mean = 93.863 
 
Least square means for Dose :  
Group  Mean  
1.000  106.417  
10.000 416.833  
100.000 449.167  
Std Err of LS Mean = 81.288 
 
Least square means for Time (min) x Dose :  
Group   Mean  
240.000 x 1.000 282.667  
240.000 x 10.000 1568.333  
240.000 x 100.000 1401.667  
60.000 x 1.000 99.667  
60.000 x 10.000 93.000  
60.000 x 100.000 391.000  
10.000 x 1.000 12.333  
10.000 x 10.000 4.000  
10.000 x 100.000 2.000  
5.000 x 1.000 31.000  
5.000 x 10.000 2.000  
5.000 x 100.000 2.000  
Std Err of LS Mean = 162.576 
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All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparisons for factor: Time (min) 
Comparison Diff of Means  p q  P  P<0.050  
240.000 vs. 10.000 1078.111 4 11.486 <0.001 Yes  
240.000 vs. 5.000 1072.556 4 11.427 <0.001 Yes  
240.000 vs. 60.000 889.667 4 9.478  <0.001 Yes  
60.000 vs. 10.000 188.444 4 2.008  0.500  No  
60.000 vs. 5.000 182.889 4 1.948  0.525  Do Not Test  
5.000 vs. 10.000 5.556  4 0.0592 1.000  Do Not Test  
 
Comparisons for factor: Dose 
Comparison Diff of Means  p q  P  P<0.050  
100.000 vs. 1.000 342.750 3 4.216  0.017  Yes  
100.000 vs. 10.000 32.333 3 0.398  0.958  No  
10.000 vs. 1.000 310.417 3 3.819  0.032  Yes  
 
Comparisons for factor: Dose within 240 
Comparison Diff of Means  p q  P  P<0.05  
10.000 vs. 1.000 1285.667 3 7.908  <0.001 Yes  
10.000 vs. 100.000 166.667 3 1.025  0.751  No  
100.000 vs. 1.000 1119.000 3 6.883  <0.001 Yes  
 
Comparisons for factor: Dose within 60 
Comparison Diff of Means  p q  P  P<0.05  
100.000 vs. 10.000 298.000 3 1.833  0.411  No  
100.000 vs. 1.000 291.333 3 1.792  0.427  Do Not Test  
1.000 vs. 10.000 6.667  3 0.0410 1.000  Do Not Test  
 
Comparisons for factor: Dose within 10 
Comparison Diff of Means  p q  P  P<0.05  
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1.000 vs. 100.000 10.333 3 0.0636 0.999  No  
1.000 vs. 10.000 8.333  3 0.0513 0.999  Do Not Test  
10.000 vs. 100.000 2.000  3 0.0123 1.000  Do Not Test  
 
Comparisons for factor: Dose within 5 
Comparison Diff of Means  p q  P  P<0.05  
1.000 vs. 100.000 29.000 3 0.178  0.991  No  
1.000 vs. 10.000 29.000 3 0.178  0.991  Do Not Test  
10.000 vs. 100.000 0.000  3 0.000  1.000  Do Not Test  
 
Comparisons for factor: Time (min) within 1 
Comparison Diff of Means  p q  P  P<0.05  
240.000 vs. 10.000 270.333 4 1.663  0.648  No  
240.000 vs. 5.000 251.667 4 1.548  0.696  Do Not Test  
240.000 vs. 60.000 183.000 4 1.126  0.856  Do Not Test  
60.000 vs. 10.000 87.333 4 0.537  0.981  Do Not Test  
60.000 vs. 5.000 68.667 4 0.422  0.991  Do Not Test  
5.000 vs. 10.000 18.667 4 0.115  1.000  Do Not Test  
 
Comparisons for factor: Time (min) within 10 
Comparison Diff of Means  p q  P  P<0.05  
240.000 vs. 5.000 1566.333 4 9.634  <0.001 Yes  
240.000 vs. 10.000 1564.333 4 9.622  <0.001 Yes  
240.000 vs. 60.000 1475.333 4 9.075  <0.001 Yes  
60.000 vs. 5.000 91.000 4 0.560  0.979  No  
60.000 vs. 10.000 89.000 4 0.547  0.980  Do Not Test  
10.000 vs. 5.000 2.000  4 0.0123 1.000  Do Not Test  
 
Comparisons for factor: Time (min) within 100 
Comparison Diff of Means  p q  P  P<0.05  
240.000 vs. 5.000 1399.667 4 8.609  <0.001 Yes  
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240.000 vs. 10.000 1399.667 4 8.609  <0.001 Yes  
240.000 vs. 60.000 1010.667 4 6.217  0.001  Yes  
60.000 vs. 5.000 389.000 4 2.393  0.350  No  
60.000 vs. 10.000 389.000 4 2.393  0.350  Do Not Test  
10.000 vs. 5.000 0.000  4 0.000  1.000  Do Not Test 
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A2. Effect of the Presence or Absence of Serum Proteins on 
SPIO Uptake 
 
 
Source of 
Variation 
 DF   SS   MS    F    P  
[iron] 3 3133692587.125 1044564195.708 481.432 <0.001 
FBS 1 97433310.375 97433310.375 44.906 <0.001 
[iron] x 
FBS 
3 317465364.458 105821788.153 48.772 <0.001 
Residual 16 34715270.000 2169704.375   
Total 23 3583306531.958 155795936.172   
  
The difference in the mean values among the different levels of [iron] is greater 
than would be expected by chance after allowing for effects of differences in 
FBS.  There is a statistically significant difference (P = <0.001).   
 
The difference in the mean values among the different levels of FBS is greater 
than would be expected by chance after allowing for effects of differences in 
[iron].  There is a statistically significant difference (P = <0.001).   
 
The effect of different levels of [iron] depends on what level of FBS is present.  
There is a statistically significant interaction between [iron] and FBS.  (P = 
<0.001) 
 
Power of performed test with alpha = 0.0500:  for [iron] :   1.000 
Power of performed test with alpha = 0.0500:  for FBS :   1.000 
Power of performed test with alpha = 0.0500:  for [iron] x FBS :  1.000 
 
Least square means for [iron] :  
Group Mean  
100.000 27881.667  
10.000 5212.000  
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1.000  524.500  
0.000  0.000  
Std Err of LS Mean = 601.346 
 
Least square means for FBS :  
Group Mean  
1.000  10419.417  
0.000  6389.667  
Std Err of LS Mean = 425.216 
 
Least square means for [iron] x FBS :  
Group Mean  
100.000 x 1.000 36195.333  
100.000 x 0.000 19568.000  
10.000 x 1.000 5070.333  
10.000 x 0.000 5353.667  
1.000 x 1.000 412.000  
1.000 x 0.000 637.000  
0.000 x 1.000 0.000  
0.000 x 0.000 0.000  
Std Err of LS Mean = 850.432 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparisons for factor: [iron] 
Comparison Diff of Means  p     q      P  P<0.050  
100.000 vs. 0.000 27881.667 4 46.365 <0.001 Yes  
100.000 vs. 1.000 27357.167 4 45.493 <0.001 Yes  
100.000 vs. 10.000 22669.667 4 37.698 <0.001 Yes  
10.000 vs. 0.000 5212.000 4 8.667  <0.001 Yes  
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10.000 vs. 1.000 4687.500 4 7.795  <0.001 Yes  
1.000 vs. 0.000 524.500 4 0.872  0.925  No  
 
Comparisons for factor: FBS 
Comparison  Diff of Means  p     q      P  P<0.050  
1.000 vs. 0.000 4029.750  2 9.477 <0.001 Yes  
 
Comparisons for factor: FBS within 100 
Comparison  Diff of Means  p q P  P<0.05  
1.000 vs. 0.000 16627.333  2 19.55 <0.001 Yes  
 
Comparisons for factor: FBS within 10 
Comparison  Diff of  Means p q P  P<0.05  
0.000 vs. 1.000 283.333  2 0.333 0.817  No  
 
Comparisons for factor: FBS within 1 
Comparison  Diff of Means  p q P  P<0.05  
0.000 vs. 1.000 225.000  2 0.265 0.854  No  
 
Comparisons for factor: FBS within 0 
Comparison Diff of Means p q P P<0.05  
1.000 vs. 0.000 0.000 2 0.000 1.000 No  
 
Comparisons for factor: [iron] within 1 
Comparison Diff of Means p q   P  P<0.05  
100.000 vs. 0.000 36195.333 4 42.561 <0.001 Yes  
100.000 vs. 1.000 35783.333 4 42.077 <0.001 Yes  
100.000 vs. 10.000 31125.000 4 36.599 <0.001 Yes  
10.000 vs. 0.000 5070.333 4 5.962  0.003  Yes  
10.000 vs. 1.000 4658.333 4 5.478  0.007  Yes  
1.000 vs. 0.000 412.000 4 0.484  0.986  No  
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 Comparisons for factor: [iron] within 0 
Comparison Diff of Means  p q  P  P<0.05  
100.000 vs. 0.000 19568.000 4 23.009 <0.001 Yes  
100.000 vs. 1.000 18931.000 4 22.260 <0.001 Yes  
100.000 vs. 10.000 14214.333 4 16.714 <0.001 Yes  
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A3. Effect of Cytochalasin B on Iron Uptake 
Data source: Data 1 in Notebook 
Balanced Design 
Dependent Variable: Blue Area  
Normality Test:  Passed (P = 0.019) 
Equal Variance Test: Passed (P = 0.029) 
 
Source of 
Variation 
 DF   SS   MS    F    P  
[iron] 3 4642205912.167 1547401970.722 117.310 <0.001 
CYTO 
1mcg/ml 
1 53133504.167 53133504.167 4.028 0.062 
[iron] x 
CYTO 
1mcg/ml 
3 191873468.167 63957822.722 4.849 0.014 
Residual 16 211051657.333 13190728.583   
Total 23 5098264541.833 221663675.732   
    
 
 
The difference in the mean values among the different levels of [iron] is greater 
than would be expected by chance after allowing for effects of differences in 
CYTO 1mcg/ml.  There is a statistically significant difference (P = <0.001).  To 
isolate which group(s) differ from the others use a multiple comparison 
procedure. 
 
The difference in the mean values among the different levels of CYTO 1mcg/ml 
is not great enough to exclude the possibility that the difference is just due to 
random sampling variability after allowing for the effects of differences in [iron].  
There is not a statistically significant difference (P = 0.062). 
 
 109
The effect of different levels of [iron] depends on what level of CYTO 1mcg/ml is 
present.  There is a statistically significant interaction between [iron] and CYTO 
1mcg/ml.  (P = 0.014) 
 
Power of performed test with alpha = 0.0500:  for [iron] : 1.000 
Power of performed test with alpha = 0.0500:  for CYTO 1mcg/ml : 0.360 
Power of performed test with alpha = 0.0500:  for [iron] x CYTO 1mcg/ml : 0.715 
 
Least square means for [iron] :  
Group  Mean  
100.000 34951.500  
10.000 11005.667  
1.000  1877.667  
0.000  21.500  
Std Err of LS Mean = 1482.719 
 
Least square means for CYTO 1mcg/ml :  
Group  Mean  
0.000  13452.000  
1.000  10476.167  
Std Err of LS Mean = 1048.440 
 
Least square means for [iron] x CYTO 1mcg/ml :  
Group Mean  
100.000 x 0.000 41322.333  
100.000 x 1.000 28580.667  
10.000 x 0.000 10512.000  
10.000 x 1.000 11499.333  
1.000 x 0.000 1930.667  
1.000 x 1.000 1824.667   
0.000 x 1.000 0.000 
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0.000 x 0.000 43.000  
Std Err of LS Mean = 2096.881 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparisons for factor: [iron] 
Comparison Diff of Means  p q  P  P<0.050  
100.000 vs. 0.000 34930.000 4 23.558 <0.001 Yes  
100.000 vs. 1.000 33073.833 4 22.306 <0.001 Yes  
100.000 vs. 10.000 23945.833 4 16.150 <0.001 Yes  
10.000 vs. 0.000 10984.167 4 7.408  <0.001 Yes  
10.000 vs. 1.000 9128.000 4 6.156  0.003  Yes  
1.000 vs. 0.000 1856.167 4 1.252  0.813  No  
 
Comparisons for factor: CYTO 1mcg/ml within 100 
Comparison Diff of Means  p q P  P<0.05  
0.000 vs. 1.000 12741.667 2 6.076 <0.001 Yes  
 
Comparisons for factor: CYTO 1mcg/ml within 10 
Comparison Diff of Means p q P P<0.05  
1.000 vs. 0.000 987.333 2 0.471 0.744 No  
 
Comparisons for factor: CYTO 1mcg/ml within 1 
Comparison Diff of Means  p q  P P<0.05  
0.000 vs. 1.000 106.000 2 0.0506 0.972 No  
 
Comparisons for factor: CYTO 1mcg/ml within 0 
Comparison Diff of Means  p q  P P<0.05  
0.000 vs. 1.000 43.000 2 0.0205 0.989 No  
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Comparisons for factor: [iron] within 0 
Comparison Diff of Means  p q  P  P<0.05  
100.000 vs. 0.000 41279.333 4 19.686 <0.001 Yes  
100.000 vs. 1.000 39391.667 4 18.786 <0.001 Yes  
100.000 vs. 10.000 30810.333 4 14.693 <0.001 Yes  
10.000 vs. 0.000 10469.000 4 4.993  0.013  Yes  
10.000 vs. 1.000 8581.333 4 4.092  0.047  Yes  
1.000 vs. 0.000 1887.667 4 0.900  0.919  No  
 
Comparisons for factor: [iron] within 1 
Comparison Diff of Means  p q  P  P<0.05  
100.000 vs. 0.000 28580.667 4 13.630 <0.001 Yes  
100.000 vs. 1.000 26756.000 4 12.760 <0.001 Yes  
100.000 vs. 10.000 17081.333 4 8.146  <0.001 Yes  
10.000 vs. 0.000 11499.333 4 5.484  0.007  Yes  
10.000 vs. 1.000 9674.667 4 4.614  0.023  Yes  
1.000 vs. 0.000 1824.667 4 0.870  0.926  No 
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A4. Effect of Blocking Mannose Receptors with Mannan 
Two Way Analysis of Variance  
Data source: Data 1 in Notebook 
 
Source of 
Variation 
 DF   SS   MS    F    P  
Mannan 
Block 
1 5422602.667 5422602.667 1.888 0.188 
[iron] 3 178080852.333 59360284.111 20.663 <0.001 
Mannan 
Block x 
[iron] 
3 21179777.667 7059925.889 2.458 0.100 
Residual 16 45964028.667 2872751.792   
Total 23 250647261.333 10897707.014   
    
The difference in the mean values among the different levels of Mannan Block is 
not great enough to exclude the possibility that the difference is just due to 
random sampling variability after allowing for the effects of differences in [iron].  
There is not a statistically significant difference (P = 0.188). 
 
The difference in the mean values among the different levels of [iron] is greater 
than would be expected by chance after allowing for effects of differences in 
Mannan Block.  There is a statistically significant difference (P = <0.001).  To 
isolate which group(s) differ from the others use a multiple comparison 
procedure. 
 
The effect of different levels of Mannan Block does not depend on what level of 
[iron] is present.  There is not a statistically significant interaction between 
Mannan Block and [iron].  (P = 0.100) 
 
Power of performed test with alpha = 0.0500:  for Mannan Block : 0.135 
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Power of performed test with alpha = 0.0500:  for [iron] : 1.000 
Power of performed test with alpha = 0.0500:  for Mannan Block x [iron] : 0.306 
 
Least square means for Mannan Block :  
Group  Mean  
0.000  1309.833  
1.000  2260.500  
Std Err of LS Mean = 489.281 
 
Least square means for [iron] :  
Group  Mean  
100.000 6493.167  
10.000 498.333  
1.000  132.667  
0.000  16.500  
Std Err of LS Mean = 691.948 
 
Least square means for Mannan Block x [iron] :  
Group   Mean  
0.000 x 100.000 4393.000  
0.000 x 10.000 599.333  
0.000 x 1.000 245.000  
0.000 x 0.000 2.000  
1.000 x 100.000 8593.333  
1.000 x 10.000 397.333   
1.000 x 0.000 31.000 
1.000 x 1.000 20.333  
Std Err of LS Mean = 978.562 
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All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparisons for factor: [iron] 
Comparison Diff of Means  p q P  P<0.050  
100.000 vs. 0.000 6476.667 4 9.360 <0.001 Yes  
100.000 vs. 1.000 6360.500 4 9.192 <0.001 Yes  
100.000 vs. 10.000 5994.833 4 8.664 <0.001 Yes  
10.000 vs. 0.000 481.833 4 0.696 0.960  No  
10.000 vs. 1.000 365.667 4 0.528 0.982  Do Not Test  
1.000 vs. 0.000 116.167 4 0.168 0.999  Do Not Test  
 
A result of "Do Not Test" occurs for a comparison when no significant difference 
is found between two means that enclose that comparison.  For example, if you 
had four means sorted in order, and found no difference between means 4 vs. 2, 
then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 vs. 
3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed 
means is a procedural rule, and a result of Do Not Test should be treated as if 
there is no significant difference between the means, even though one may 
appear to exist. 
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A5. Effect of Interleuken-4 on Macrophage Uptake of Iron Oxide 
a. IL-4 at 10 ng/ml 
 
 
Source of 
Variation 
 DF   SS   MS    F    P  
IL-4 (10 
ng/ml) 
1 20276816.667 20276816.667 1.692 0.212 
[iron] 3 4540930168.833 1513643389.611 126.318 <0.001 
IL-4 (10 
ng/ml) x 
[iron] 
3 145048807.667 48349602.556 4.035 0.026 
Residual 16 191724197.333 11982762.333   
Total 23 4897979990.500 212955651.761   
 
 
The difference in the mean values among the different levels of IL-4 (10 ng/ml) is 
not great enough to exclude the possibility that the difference is just due to 
random sampling variability after allowing for the effects of differences in [iron].  
There is not a statistically significant difference (P = 0.212). 
 
The difference in the mean values among the different levels of [iron] is greater 
than would be expected by chance after allowing for effects of differences in IL-4 
(10 ng/ml).  There is a statistically significant difference (P = <0.001).  To isolate 
which group(s) differ from the others use a multiple comparison procedure. 
 
The effect of different levels of IL-4 (10 ng/ml) depends on what level of [iron] is 
present.  There is a statistically significant interaction between IL-4 (10 ng/ml) 
and [iron].  (P = 0.026) 
 
Power of performed test with alpha = 0.0500:  for IL-4 (10 ng/ml) : 0.116 
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Power of performed test with alpha = 0.0500:  for [iron] : 1.000 
Power of performed test with alpha = 0.0500:  for IL-4 (10 ng/ml) x [iron] : 0.597 
 
Least square means for IL-4 (10 ng/ml) :  
Group  Mean  
0.000  10158.583  
1.000  11996.917  
Std Err of LS Mean = 999.282 
 
Least square means for [iron] :  
Group  Mean  
100.000 34376.500  
10.000 7857.667  
1.000  2049.500  
0.000  27.333  
Std Err of LS Mean = 1413.197 
 
Least square means for IL-4 (10 ng/ml) x [iron] :  
Group   Mean  
0.000 x 100.000 29232.667  
0.000 x 10.000 8703.333  
0.000 x 1.000 2666.000  
0.000 x 0.000 32.333  
1.000 x 100.000 39520.333 
1.000 x 10.000 7012.000   
1.000 x 0.000 22.333 
1.000 x 1.000 1433.000  
Std Err of LS Mean = 1998.563 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
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Comparisons for factor: IL-4 (10 ng/ml) 
Comparison Diff of Means  p q P  P<0.050  
1.000 vs. 0.000 1838.333 2 1.840 0.212  No  
 
Comparisons for factor: [iron] 
Comparison Diff of Means  p q  P  P<0.050  
100.000 vs. 0.000 34349.167 4 24.306 <0.001 Yes  
100.000 vs. 1.000 32327.000 4 22.875 <0.001 Yes  
100.000 vs. 10.000 26518.833 4 18.765 <0.001 Yes  
10.000 vs. 0.000 7830.333 4 5.541  0.006  Yes  
10.000 vs. 1.000 5808.167 4 4.110  0.046  Yes  
1.000 vs. 0.000 2022.167 4 1.431  0.745  No  
 
Comparisons for factor: [iron] within 0 
Comparison Diff of Means  p q  P  P<0.05  
100.000 vs. 0.000 29200.333 4 14.611 <0.001 Yes  
100.000 vs. 1.000 26566.667 4 13.293 <0.001 Yes  
100.000 vs. 10.000 20529.333 4 10.272 <0.001 Yes  
10.000 vs. 0.000 8671.000 4 4.339  0.034  Yes  
10.000 vs. 1.000 6037.333 4 3.021  0.184  No  
1.000 vs. 0.000 2633.667 4 1.318  0.789  No  
 
Comparisons for factor: [iron] within 1 
Comparison Diff of Means  p q  P  P<0.05  
100.000 vs. 0.000 39498.000 4 19.763 <0.001 Yes  
100.000 vs. 1.000 38087.333 4 19.057 <0.001 Yes  
100.000 vs. 10.000 32508.333 4 16.266 <0.001 Yes  
10.000 vs. 0.000 6989.667 4 3.497  0.103  No  
10.000 vs. 1.000 5579.000 4 2.792  0.238  Do Not Test  
1.000 vs. 0.000 1410.667 4 0.706  0.958  Do Not Test  
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 Comparisons for factor: IL-4 (10 ng/ml) within 100 
Comparison Diff of Means  p q  P  P<0.05  
1.000 vs. 0.000 10287.667 2 5.148  0.002  Yes  
 
 
Comparisons for factor: IL-4 (10 ng/ml) within 10 
Comparison Diff of Means  p q  P  P<0.05  
0.000 vs. 1.000 1691.333 2 0.846  0.558  No 
 
Comparisons for factor: IL-4 (10 ng/ml) within 1 
Comparison Diff of Means  p q  P  P<0.05 
0.000 vs. 1.000 1233.000 2 0.617  0.669  No  
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A6. Effect of Interleuken-4 on Macrophage Uptake of Iron Oxide 
b. IL-4 (20 ng/ml) 
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
IL-4 (20 
ng/ml) 
1 93750.000 93750.000 0.00461 0.947 
[iron] 3 4781933262.333 1593977754.111 78.450 <0.001 
IL-4 (20 
ng/ml) x 
[iron] 
3 5172533.000 1724177.667 0.0849 0.967 
Residual 16 325095190.000 20318449.375   
Total 23 5112294735.333 222273684.145   
 
The difference in the mean values among the different levels of IL-4 (20 ng/ml) is 
not great enough to exclude the possibility that the difference is just due to 
random sampling variability after allowing for the effects of differences in [iron].  
There is not a statistically significant difference (P = 0.947). 
 
The difference in the mean values among the different levels of [iron] is greater 
than would be expected by chance after allowing for effects of differences in IL-4 
(20 ng/ml).  There is a statistically significant difference (P = <0.001).  To isolate 
which group(s) differ from the others use a multiple comparison procedure.The 
effect of different levels of IL-4 (20 ng/ml) does not depend on what level of [iron] 
is present.  There is not a statistically significant interaction between IL-4 (20 
ng/ml) and [iron].  (P = 0.967)Power of performed test with alpha = 0.0500:  for 
IL-4 (20 ng/ml) : 0.0500 
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Power of performed test with alpha = 0.0500:  for [iron] : 1.000 
Power of performed test with alpha = 0.0500:  for IL-4 (20 ng/ml) x [iron] : 0.0500 
 
Least square means for IL-4 (20 ng/ml) :  
Group  Mean  
0.000  11560.333  
1.000  11435.333  
Std Err of LS Mean = 1301.232 
 
Least square means for [iron] :  
Group  Mean  
100.000 34974.333  
10.000 10086.833  
1.000  917.167  
0.000  13.000  
Std Err of LS Mean = 1840.220 
 
Least square means for IL-4 (20 ng/ml) x [iron] :  
Group   Mean  
0.000 x 100.000 34482.667  
0.000 x 10.000 10882.667  
0.000 x 1.000 866.000  
0.000 x 0.000 10.000  
1.000 x 100.000 35466.000  
1.000 x 10.000 9291.000   
1.000 x 0.000 16.000 
1.000 x 1.000 968.333  
Std Err of LS Mean = 2602.464 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
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Comparisons for factor: IL-4 (20 ng/ml) 
Comparison Diff of Means  p q  P P<0.050  
0.000 vs. 1.000 125.000 2 0.0961 0.947 No  
 
Comparisons for factor: [iron] 
Comparison Diff of Means  p q  P  P<0.050  
100.000 vs. 0.000 34961.333 4 18.998 <0.001 Yes  
100.000 vs. 1.000 34057.167 4 18.507 <0.001 Yes  
100.000 vs. 10.000 24887.500 4 13.524 <0.001 Yes  
10.000 vs. 0.000 10073.833 4 5.474  0.007  Yes  
10.000 vs. 1.000 9169.667 4 4.983  0.014  Yes  
1.000 vs. 0.000 904.167 4 0.491  0.985  No 
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A7. Effect of Interleuken-4 on Macrophage Uptake of Iron Oxide 
c. IL-4 (40 ng/ml) 
 
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
IL-4 (40 
ng/ml) 
1 114821876.042 114821876.042 5.514 0.032 
[iron] 3 5574749793.125 1858249931.042 89.239 <0.001 
IL-4 (40 
ng/ml) x 
[iron] 
3 131018250.125 43672750.042 2.097 0.141 
Residual 16 333171619.333 20823226.208   
Total 23 6153761538.625 267554849.505   
    
 
 
The difference in the mean values among the different levels of IL-4 (40 ng/ml) is 
greater than would be expected by chance after allowing for effects of differences 
in [iron].  There is a statistically significant difference (P = 0.032).  To isolate 
which group(s) differ from the others use a multiple comparison procedure. 
 
The difference in the mean values among the different levels of [iron] is greater 
than would be expected by chance after allowing for effects of differences in IL-4 
(40 ng/ml).  There is a statistically significant difference (P = <0.001).  To isolate 
which group(s) differ from the others use a multiple comparison procedure. 
 
The effect of different levels of IL-4 (40 ng/ml) does not depend on what level of 
[iron] is present.  There is not a statistically significant interaction between IL-4 
(20 ng/ml) and [iron].  (P = 0.141) 
 
Power of performed test with alpha = 0.0500:  for IL-4 (40 ng/ml) : 0.508 
Power of performed test with alpha = 0.0500:  for [iron] : 1.000 
Power of performed test with alpha = 0.0500:  for IL-4 (40 ng/ml) x [iron] : 0.236 
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Least square means for IL-4 (40 ng/ml) :  
Group  Mean  
0.000  10198.833  
1.000  14573.417  
Std Err of LS Mean = 1317.296 
 
Least square means for [iron] :  
Group  Mean  
100.000 37711.833  
10.000 10947.333  
1.000  873.333  
0.000  12.000  
Std Err of LS Mean = 1862.938 
 
Least square means for IL-4 (40 ng/ml) x [iron] :  
Group     Mean  
0.000 x 100.000   31911.667  
0.000 x 10.000   8251.333  
0.000 x 1.000   622.333  
1.000 x 100.000   43512.000  
1.000 x 10.000   13643.333  
1.000 x 1.000   1124.333  
1.000 x 0.000   14.000  
Std Err of LS Mean = 2634.592 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparisons for factor: IL-4 (40 ng/ml) 
Comparison Diff of Means  p q  P  P<0.050  
1.000 vs. 0.000 4374.583 2 3.321  0.032  Yes  
 
 
Comparisons for factor: [iron] 
Comparison Diff of Means  p q  P  P<0.050  
100.000 vs. 0.000 37699.833 4 20.237 <0.001 Yes  
100.000 vs. 1.000 36838.500 4 19.774 <0.001 Yes  
100.000 vs. 10.000 26764.500 4 14.367 <0.001 Yes  
10.000 vs. 0.000 10935.333 4 5.870  0.004  Yes  
10.000 vs. 1.000 10074.000 4 5.408  0.007  Yes  
1.000 vs. 0.000 861.333 4 0.462  0.988  No 
 
1.000 x 10.000 13643.333 1.000 x 1.000 1124.333  
1.000 x 0.000 14.000  
Std Err of LS Mean = 2634.592 
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All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparisons for factor: IL-4 (40 ng/ml) 
Comparison Diff of Means p q P P<0.050  
1.000 vs. 0.000 4374.583 2 3.321 0.032 Yes  
 
 
Comparisons for factor: [iron] 
Comparison Diff of Means  p     q       P  P<0.050  
100.000 vs. 0.000 37699.833 4 20.237 <0.001 Yes  
100.000 vs. 1.000 36838.500 4 19.774 <0.001 Yes  
100.000 vs. 10.000 26764.500 4 14.367 <0.001 Yes  
10.000 vs. 0.000 10935.333 4 5.870  0.004  Yes  
10.000 vs. 1.000 10074.000 4 5.408  0.007  Yes  
1.000 vs. 0.000 861.333 4 0.462  0.988  No  
 
 
Comparisons for factor: [iron] within 0 
Comparison Diff of Means  p     q      P  P<0.05  
100.000 vs. 0.000 31901.667 4 12.109 <0.001 Yes  
100.000 vs. 1.000 31289.333 4 11.876 <0.001 Yes  
100.000 vs. 10.000 23660.333 4 8.981  <0.001 Yes  
10.000 vs. 0.000 8241.333 4 3.128  0.162  No  
10.000 vs. 1.000 7629.000 4 2.896  0.212        Do Not Test  
1.000 vs. 0.000 612.333 4 0.232  0.998        Do Not Test  
 
 
Comparisons for factor: [iron] within 1 
Comparison Diff of Means  p     q       P  P<0.05  
100.000 vs. 0.000 43498.000 4 16.510 <0.001 Yes  
100.000 vs. 1.000 42387.667 4 16.089 <0.001 Yes  
100.000 vs. 10.000 29868.667 4 11.337 <0.001 Yes  
10.000 vs. 0.000 13629.333 4 5.173  0.010  Yes  
10.000 vs. 1.000 12519.000 4 4.752  0.019  Yes  
1.000 vs. 0.000 1110.333 4 0.421  0.991  No  
 
 
Comparisons for factor: IL-4 (40 ng/ml) within 100 
Comparison Diff of Means  p    q      P  P<0.05  
1.000 vs. 0.000 11600.333 2 4.403  0.007  Yes  
 
 
Comparisons for factor: IL-4 (40 ng/ml) within 10 
Comparison Diff of Means  p    q     P  P<0.05  
1.000 vs. 0.000 5392.000 2 2.047  0.167  No  
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Comparisons for factor: IL-4 (40 ng/ml) within 1 
Comparison Diff of Means  p q     P  P<0.05  
1.000 vs. 0.000 502.000 2 0.191  0.895  No  
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A8. Effect of Human Interferon Gamma on Macrophage Uptake of 
Iron Oxide 
a. IFN-γ at 10 U/ml 
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
IFN-γ 
(10u/ml) 
1 3711493.500 3711493.500 0.346 0.565 
[iron] 3 4715548409.500 1571849469.833 146.523 <0.001 
IFN-γ 
(10u/ml) x 
[iron] 
3 1652630.833 550876.944 0.0514 0.984 
Residual 16 171642074.667 10727629.667   
Total 23 4892554608.500 212719765.587   
   
 
 
The difference in the mean values among the different levels of IFN-g (10u/ml) is 
not great enough to exclude the possibility that the difference is just due to 
random sampling variability after allowing for the effects of differences in [iron].  
There is not a statistically significant difference (P = 0.565). 
 
The difference in the mean values among the different levels of [iron] is greater 
than would be expected by chance after allowing for effects of differences in IFN-
γ (10u/ml).  There is a statistically significant difference (P = <0.001).  To isolate 
which group(s) differ from the others use a multiple comparison procedure. 
 
The effect of different levels of IFN-γ (10u/ml) does not depend on what level of 
[iron] is present.  There is not a statistically significant interaction between IFN-g 
(10u/ml) and [iron].  (P = 0.984) 
 
Power of performed test with alpha = 0.0500:  for IFN-g (10u/ml) : 0.0500 
Power of performed test with alpha = 0.0500:  for [iron] : 1.000 
Power of performed test with alpha = 0.0500:  for IFN-g (10u/ml) x [iron] : 0.0500 
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Least square means for IFN-γ (10u/ml) :  
Group  Mean  
0.000  11087.500  
1.000  11874.000  
Std Err of LS Mean = 945.499 
 
Least square means for [iron] :  
Group  Mean  
100.000 34979.667  
10.000 9329.667  
1.000  1592.167  
0.000  21.500  
Std Err of LS Mean = 1337.138 
 
Least square means for IFN-γ (10u/ml) x [iron] :  
Group   Mean  
0.000 x 100.000 34630.667  
0.000 x 10.000 8618.000  
0.000 x 1.000 1076.667  
0.000 x 0.000 24.667  
1.000 x 100.000 35328.667  
1.000 x 10.000 10041.333  
1.000 x 1.000 2107.667  
1.000 x 0.000 18.333  
Std Err of LS Mean = 1890.999 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparisons for factor: [iron] 
Comparison Diff of Means  p q  P  P<0.050  
100.000 vs. 0.000 34958.167 4 26.144 <0.001 Yes  
100.000 vs. 1.000 33387.500 4 24.969 <0.001 Yes  
100.000 vs. 10.000 25650.000 4 19.183 <0.001 Yes  
10.000 vs. 0.000 9308.167 4 6.961  <0.001 Yes  
10.000 vs. 1.000 7737.500 4 5.787  0.004  Yes  
1.000 vs. 0.000 1570.667 4 1.175  0.839  No  
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A9. Effect of Human Interferon Gamma on Macrophage Uptake of 
Iron Oxide 
 
b. IFN-γ at 500 U/ml   
 
Two Way Analysis of Variance 
 
Source of 
Variation 
 DF   SS   MS    F    P  
IFN-γ 
(500u/ml) 
1 4428.167 4428.167 0.000340 0.986 
[iron] 3 3562854979.333 1187618326.444 91.275 <0.001 
IFN-γ 
(500u/ml) 
x [iron] 
3 17911468.500 5970489.500 0.459 0.715 
Residual 16 208182604.000 13011412.750   
Total 23 3788953480.000 164737107.826   
   
 
 
The difference in the mean values among the different levels of IFN-γ (500u/ml) 
is not great enough to exclude the possibility that the difference is just due to 
random sampling variability after allowing for the effects of differences in [iron].  
There is not a statistically significant difference (P = 0.986). 
 
The difference in the mean values among the different levels of [iron] is greater 
than would be expected by chance after allowing for effects of differences in IFN-
γ (500u/ml).  There is a statistically significant difference (P = <0.001).  To isolate 
which group(s) differ from the others use a multiple comparison procedure. 
 
The effect of different levels of IFN-γ (500u/ml) does not depend on what level of 
[iron] is present.  There is not a statistically significant interaction between IFN-γ 
(500u/ml) and [iron].  (P = 0.715) 
 
Power of performed test with alpha = 0.0500:  for IFN-γ (500u/ml) : 0.0500 
Power of performed test with alpha = 0.0500:  for [iron] : 1.000 
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Power of performed test with alpha = 0.0500:  for IFN-γ (500u/ml) x [iron] : 0.0500 
 
Least square means for IFN-γ (500u/ml) :  
Group  Mean  
0.000  11550.083  
1.000  11522.917  
Std Err of LS Mean = 1041.290 
 
Least square means for [iron] :  
Group  Mean  
100.000 30172.333  
10.000 14631.667  
1.000  1310.000  
0.000  32.000  
Std Err of LS Mean = 1472.606 
 
Least square means for IFN-γ (500u/ml) x [iron] :  
Group   Mean  
0.000 x 100.000 31553.667  
0.000 x 10.000 13655.667  
0.000 x 1.000 956.000  
0.000 x 0.000 35.000  
1.000 x 100.000 28791.000  
1.000 x 10.000 15607.667  
1.000 x 1.000 1664.000  
1.000 x 0.000 29.000  
Std Err of LS Mean = 2082.580 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparisons for factor: [iron] 
Comparison Diff of Means  p q  P  P<0.050  
100.000 vs. 0.000 30140.333 4 20.467 <0.001 Yes  
100.000 vs. 1.000 28862.333 4 19.599 <0.001 Yes  
100.000 vs. 10.000 15540.667 4 10.553 <0.001 Yes  
10.000 vs. 0.000 14599.667 4 9.914  <0.001 Yes  
10.000 vs. 1.000 13321.667 4 9.046  <0.001 Yes  
1.000 vs. 0.000 1278.000 4 0.868  0.926  No 
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A10. Effect of Human Interferon Gamma on Macrophage Uptake 
of Iron Oxide 
 
b. IFN-γ at 500 U/ml   
 
Two Way Analysis of Variance 
 
Source of 
Variation 
 DF   SS   MS    F    P  
IFN-γ 
(500u/ml) 
1 4428.167 4428.167 0.000340 0.986 
[iron] 3 3562854979.333 1187618326.444 91.275 <0.001 
IFN-γ 
(500u/ml) 
x [iron] 
3 17911468.500 5970489.500 0.459 0.715 
Residual 16 208182604.000 13011412.750   
Total 23 3788953480.000 164737107.826   
   
 
 
The difference in the mean values among the different levels of IFN-γ (500u/ml) 
is not great enough to exclude the possibility that the difference is just due to 
random sampling variability after allowing for the effects of differences in [iron].  
There is not a statistically significant difference (P = 0.986). 
 
The difference in the mean values among the different levels of [iron] is greater 
than would be expected by chance after allowing for effects of differences in IFN-
γ (500u/ml).  There is a statistically significant difference (P = <0.001).  To isolate 
which group(s) differ from the others use a multiple comparison procedure. 
 
The effect of different levels of IFN-γ (500u/ml) does not depend on what level of 
[iron] is present.  There is not a statistically significant interaction between IFN-γ 
(500u/ml) and [iron].  (P = 0.715) 
 
Power of performed test with alpha = 0.0500:  for IFN-γ (500u/ml) : 0.0500 
Power of performed test with alpha = 0.0500:  for [iron] : 1.000 
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Power of performed test with alpha = 0.0500:  for IFN-γ (500u/ml) x [iron] : 0.0500 
 
Least square means for IFN-γ (500u/ml) :  
Group  Mean  
0.000  11550.083  
1.000  11522.917  
Std Err of LS Mean = 1041.290 
 
Least square means for [iron] :  
Group  Mean  
100.000 30172.333  
10.000 14631.667  
1.000  1310.000  
0.000  32.000  
Std Err of LS Mean = 1472.606 
 
Least square means for IFN-γ (500u/ml) x [iron] :  
Group   Mean  
0.000 x 100.000 31553.667  
0.000 x 10.000 13655.667  
0.000 x 1.000 956.000  
0.000 x 0.000 35.000  
1.000 x 100.000 28791.000  
1.000 x 10.000 15607.667  
1.000 x 1.000 1664.000  
1.000 x 0.000 29.000  
Std Err of LS Mean = 2082.580 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparisons for factor: [iron] 
Comparison Diff of Means  p q  P  P<0.050  
100.000 vs. 0.000 30140.333 4 20.467 <0.001 Yes  
100.000 vs. 1.000 28862.333 4 19.599 <0.001 Yes  
100.000 vs. 10.000 15540.667 4 10.553 <0.001 Yes  
10.000 vs. 0.000 14599.667 4 9.914  <0.001 Yes  
10.000 vs. 1.000 13321.667 4 9.046  <0.001 Yes  
1.000 vs. 0.000 1278.000 4 0.868  0.926  No 
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A11. Effect of Human Interferon Gamma on Macrophage 
Uptake of Iron Oxide 
 
c. IFN-γ at 1000U/ml 
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
IFN-γ 1 91057312.667 91057312.667 4.726 0.045 
[iron] 3 2217676090.333 739225363.444 38.366 <0.001 
IFN-γ x 
[iron] 
3 181412470.333 60470823.444 3.138 0.055 
Residual 16 308285008.000 19267813.000   
Total 23 2798430881.333 121670907.884   
  
 
 
The difference in the mean values among the different levels of IFN-γ is greater 
than would be expected by chance after allowing for effects of differences in 
[iron].  There is a statistically significant difference (P = 0.045).  To isolate which 
group(s) differ from the others use a multiple comparison procedure. 
 
The difference in the mean values among the different levels of [iron] is greater 
than would be expected by chance after allowing for effects of differences in IFN-
γ.  There is a statistically significant difference (P = <0.001).  To isolate which 
group(s) differ from the others use a multiple comparison procedure. 
 
The effect of different levels of IFN-γ does not depend on what level of [iron] is 
present.  There is not a statistically significant interaction between IFN-g and 
[iron].  (P = 0.055) 
 
Power of performed test with alpha = 0.0500:  for IFN-γ : 0.432 
Power of performed test with alpha = 0.0500:  for [iron] : 1.000 
Power of performed test with alpha = 0.0500:  for IFN-γ x [iron] : 0.438 
 
Least square means for IFN-γ :  
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Group  Mean  
0.000  6149.500  
1.000  10045.167  
Std Err of LS Mean = 1267.143 
 
Least square means for [iron] :  
Group  Mean  
100.000 23893.167  
10.000 7777.333  
1.000  713.833  
0.000  5.000  
Std Err of LS Mean = 1792.011 
 
Least square means for IFN-γ x [iron] :  
Group   Mean  
0.000 x 100.000 17220.333  
0.000 x 10.000 6857.667  
0.000 x 1.000 516.000  
0.000 x 0.000 4.000  
1.000 x 100.000 30566.000  
1.000 x 10.000 8697.000  
1.000 x 1.000 911.667  
1.000 x 0.000 6.000  
 
Std Err of LS Mean = 2534.286 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparisons for factor: IFN-γ 
Comparison Diff of Means  p q  P  P<0.050  
1.000 vs. 0.000 3895.667 2 3.074  0.045  Yes  
 
 
Comparisons for factor: [iron] 
Comparison Diff of Means  p q  P  P<0.050  
100.000 vs. 0.000 23888.167 4 13.330 <0.001 Yes  
100.000 vs. 1.000 23179.333 4 12.935 <0.001 Yes  
100.000 vs. 10.000 16115.833 4 8.993  <0.001 Yes  
10.000 vs. 0.000 7772.333 4 4.337  0.034  Yes  
10.000 vs. 1.000 7063.500 4 3.942  0.058  No  
1.000 vs. 0.000 708.833 4 0.396  0.992  No 
 
1.000 x 1.000 911.667 1.000 x 0.000 6.000  
Std Err of LS Mean = 2534.286 
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 All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparisons for factor: IFN-g 
Comparison Diff of Means  p q  P  P<0.050  
1.000 vs. 0.000 3895.667 2 3.074  0.045  Yes  
 
 
Comparisons for factor: [iron] 
Comparison Diff of Means  p q  P  P<0.050  
100.000 vs. 0.000 23888.167 4 13.330 <0.001 Yes  
100.000 vs. 1.000 23179.333 4 12.935 <0.001 Yes  
100.000 vs. 10.000 16115.833 4 8.993  <0.001 Yes  
10.000 vs. 0.000 7772.333 4 4.337  0.034  Yes  
10.000 vs. 1.000 7063.500 4 3.942  0.058  No  
1.000 vs. 0.000 708.833 4 0.396  0.992  No  
 
 
Comparisons for factor: [iron] within 0 
Comparison Diff of Means  p q  P  P<0.05  
100.000 vs. 0.000 17216.333 4 6.793  0.001  Yes  
100.000 vs. 1.000 16704.333 4 6.591  0.001  Yes  
100.000 vs. 10.000 10362.667 4 4.089  0.047  Yes  
10.000 vs. 0.000 6853.667 4 2.704  0.262  No  
10.000 vs. 1.000 6341.667 4 2.502  0.323  Do Not Test  
1.000 vs. 0.000 512.000 4 0.202  0.999  Do Not Test  
 
 
Comparisons for factor: [iron] within 1 
Comparison Diff of Means  p q  P  P<0.05  
100.000 vs. 0.000 30560.000 4 12.059 <0.001 Yes  
100.000 vs. 1.000 29654.333 4 11.701 <0.001 Yes  
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100.000 vs. 10.000 21869.000 4 8.629  <0.001 Yes  
10.000 vs. 0.000 8691.000 4 3.429  0.112  No  
10.000 vs. 1.000 7785.333 4 3.072  0.173  Do Not Test  
1.000 vs. 0.000 905.667 4 0.357  0.994  Do Not Test  
 
 
Comparisons for factor: IFN-g within 100 
Comparison Diff of Means  p q  P  P<0.05  
1.000 vs. 0.000 13345.667 2 5.266  0.002  Yes  
 
Comparisons for factor: IFN-g within 10 
Comparison Diff of Means  p q  P  P<0.05  
1.000 vs. 0.000 1839.333 2 0.726  0.615  No  
 
Comparisons for factor: IFN-g within 1 
Comparison Diff of Means  p q  P  P<0.05  
1.000 vs. 0.000 395.667 2 0.156  0.914  No  
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A12. Effect of Angiotensin Converting Enzyme (ACE) Inhibition 
on Macrophage Uptake of Iron Oxide 
 
a. Captopril at 0.01 mM 
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
CAPT 
0.01mM 
1 1397320.042 1397320.042 0.0919 0.766 
[iron] 3 4773544524.458 1591181508.153 104.693 <0.001 
CAPT 
0.01mM x 
[iron] 
3 1533378.125 511126.042 0.0336 0.991 
Residual 16 243176560.000 15198535.000   
Total 23 5019651782.625 218245729.679   
    
 
 
The difference in the mean values among the different levels of CAPT 0.01mM is 
not great enough to exclude the possibility that the difference is just due to 
random sampling variability after allowing for the effects of differences in [iron].  
There is not a statistically significant difference (P = 0.766). 
 
The difference in the mean values among the different levels of [iron] is greater 
than would be expected by chance after allowing for effects of differences in 
CAPT 0.01mM.  There is a statistically significant difference (P = <0.001).  To 
isolate which group(s) differ from the others use a multiple comparison 
procedure. 
 
The effect of different levels of CAPT 0.01mM does not depend on what level of 
[iron] is present.  There is not a statistically significant interaction between CAPT 
0.01mM and [iron].  (P = 0.991) 
 
Power of performed test with alpha = 0.0500:  for CAPT 0.01mM : 0.0500 
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Power of performed test with alpha = 0.0500:  for [iron] : 1.000 
Power of performed test with alpha = 0.0500:  for CAPT 0.01mM x [iron] : 0.0500 
 
Least square means for CAPT 0.01mM :  
Group  Mean  
0.000  13690.417  
1.000  13207.833  
Std Err of LS Mean = 1125.409 
 
Least square means for [iron] :  
Group  Mean  
100.000 35143.000  
10.000 16752.500  
1.000  1851.333  
0.000  49.667  
Std Err of LS Mean = 1591.568 
 
Least square means for CAPT 0.01mM x [iron] :  
Group   Mean  
0.000 x 100.000 35655.333  
0.000 x 10.000 16697.333  
0.000 x 1.000 2322.000  
0.000 x 0.000 87.000  
1.000 x 100.000 34630.667  
1.000 x 10.000 16807.667  
1.000 x 1.000 1380.667  
1.000 x 0.000 12.333  
Std Err of LS Mean = 2250.817 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparisons for factor: [iron]  
Comparison Diff of Means  p q  
P  P<0.050  
100.000 vs. 0.000 35093.333 4 22.050 <0.001 Yes  
100.000 vs. 1.000 33291.667 4 20.918 <0.001 Yes  
100.000 vs. 10.000 18390.500 4 11.555 <0.001 Yes  
10.000 vs. 0.000 16702.833 4 10.495 <0.001 Yes  
10.000 vs. 1.000 14901.167 4 9.363  <0.001 Yes  
1.000 vs. 0.000 1801.667 4 1.132  0.853  No 
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A13. Effect of Angiotensin Converting Enzyme (ACE) 
Inhibition on Macrophage Uptake of Iron Oxide 
 
b. Captopril at 0.1 mM 
 
Two Way Analysis of Variance Wednesday, July 12, 2000, 19:15:23 
 
Source of 
Variation 
 DF   SS   MS    F    P  
CAPT 
0.1mM 
1 1443541.500 1443541.500 0.373 0.550 
[iron] 3 3468539248.833 1156179749.611 298.661 <0.001 
CAPT 
0.1mM x 
[iron] 
3 3719204.167 1239734.722 0.320 0.811 
Residual 16 61939300.000 3871206.250   
Total 23 3535641294.500 153723534.543   
   
 
 
The difference in the mean values among the different levels of CAPT 0.1mM is 
not great enough to exclude the possibility that the difference is just due to 
random sampling variability after allowing for the effects of differences in [iron].  
There is not a statistically significant difference (P = 0.550). 
 
The difference in the mean values among the different levels of [iron] is greater 
than would be expected by chance after allowing for effects of differences in 
CAPT 0.1mM.  There is a statistically significant difference (P = <0.001).  To 
isolate which group(s) differ from the others use a multiple comparison 
procedure. 
 
The effect of different levels of CAPT 0.1mM does not depend on what level of 
[iron] is present.  There is not a statistically significant interaction between CAPT 
0.1mM and [iron].  (P = 0.811) 
 
Power of performed test with alpha = 0.0500:  for CAPT 0.1mM : 0.0500 
Power of performed test with alpha = 0.0500:  for [iron] : 1.000 
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Power of performed test with alpha = 0.0500:  for CAPT 0.1mM x [iron] : 0.0500 
 
Least square means for CAPT 0.1mM :  
Group  Mean  
0.000  10965.000  
1.000  10474.500  
Std Err of LS Mean = 567.979 
 
Least square means for [iron] :  
Group  Mean  
100.000 30124.333  
10.000 11325.500  
1.000  1414.000  
0.000  15.167  
Std Err of LS Mean = 803.244 
 
Least square means for CAPT 0.1mM x [iron] :  
Group   Mean  
0.000 x 100.000 30880.667  
0.000 x 10.000 11797.333  
0.000 x 1.000 1157.667  
0.000 x 0.000 24.333  
1.000 x 100.000 29368.000  
1.000 x 10.000 10853.667  
1.000 x 1.000 1670.333  
1.000 x 0.000 6.000  
Std Err of LS Mean = 1135.959 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparisons for factor: [iron] 
Comparison Diff of Means  p q  P  P<0.050  
100.000 vs. 0.000 30109.167 4 37.484 <0.001 Yes  
100.000 vs. 1.000 28710.333 4 35.743 <0.001 Yes  
100.000 vs. 10.000 18798.833 4 23.404 <0.001 Yes  
10.000 vs. 0.000 11310.333 4 14.081 <0.001 Yes  
10.000 vs. 1.000 9911.500 4 12.339 <0.001 Yes  
1.000 vs. 0.000 1398.833 4 1.741  0.617  No 
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A14. Effect of Angiotensin Converting Enzyme (ACE) 
Inhibition on Macrophage Uptake of Iron Oxide 
 
c. Captopril 1.0 mM  
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
CAPT 
1.0mM 
1 1458294.000 1458294.000 0.102 0.753 
[iron] 3 5002019394.167 1667339798.056 117.156 <0.001 
CAPT 
1.0mM x 
[iron] 
3 7517576.333 2505858.778 0.176 0.911 
Residual 16 227707774.000 14231735.875   
Total 23 5238703038.500 227769697.326   
  
The difference in the mean values among the different levels of CAPT 1.0mM is 
not great enough to exclude the possibility that the difference is just due to 
random sampling variability after allowing for the effects of differences in [iron].  
There is not a statistically significant difference (P = 0.753). 
 
The difference in the mean values among the different levels of [iron] is greater 
than would be expected by chance after allowing for effects of differences in 
CAPT 1.0mM.  There is a statistically significant difference (P = <0.001).  To 
isolate which group(s) differ from the others use a multiple comparison 
procedure. 
 
The effect of different levels of CAPT 1.0mM does not depend on what level of 
[iron] is present.  There is not a statistically significant interaction between CAPT 
1.0mM and [iron].  (P = 0.911) 
 
Power of performed test with alpha = 0.0500:  for CAPT 1.0mM : 0.0500 
Power of performed test with alpha = 0.0500:  for [iron] : 1.000 
Power of performed test with alpha = 0.0500:  for CAPT 1.0mM x [iron] : 0.0500 
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Least square means for CAPT 1.0mM :  
Group  Mean  
0.000  11979.750  
1.000  12472.750  
Std Err of LS Mean = 1089.026 
 
Least square means for [iron] :  
Group  Mean  
100.000 36200.333  
10.000 10851.333  
1.000  1838.167  
0.000  15.167  
Std Err of LS Mean = 1540.116 
 
Least square means for CAPT 1.0mM x [iron] :  
Group   Mean  
0.000 x 100.000 35884.667  
0.000 x 10.000 9749.333  
0.000 x 1.000 2264.667  
0.000 x 0.000 20.333 
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A15. Effect of HMG CoA Reductase Inhibition (Mevinolin) on Macrophage 
Uptake of Iron Oxide 
 
b. Mevinolin (1.0 µM) 
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
HMG 
1.0mcM 
1 132337977.042 132337977.042 11.208 0.004 
[iron] 3 3500330496.458 1166776832.153 98.813 <0.001 
HMG 
1.0mcM x 
[iron] 
3 213200698.458 71066899.486 6.019 0.006 
Residual 16 188927352.000 11807959.500   
Total 23 4034796523.958 175425935.824   
    
The difference in the mean values among the different levels of HMG 1.0mcM is 
greater than would be expected by chance after allowing for effects of differences 
in [iron].  There is a statistically significant difference (P = 0.004).  To isolate 
which group(s) differ from the others use a multiple comparison procedure. 
 
The difference in the mean values among the different levels of [iron] is greater 
than would be expected by chance after allowing for effects of differences in 
HMG 1.0mcM.  There is a statistically significant difference (P = <0.001).  To 
isolate which group(s) differ from the others use a multiple comparison 
procedure. 
 
The effect of different levels of HMG 1.0mcM depends on what level of [iron] is 
present.  There is a statistically significant interaction between HMG 1.0mcM and 
[iron].  (P = 0.006) 
 
Power of performed test with alpha = 0.0500:  for HMG 1.0mcM : 0.865 
Power of performed test with alpha = 0.0500:  for [iron] : 1.000 
Power of performed test with alpha = 0.0500:  for HMG 1.0mcM x [iron] : 0.837 
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Least square means for HMG 1.0mcM :  
Group  Mean  
0.000  13650.000  
1.000  8953.583  
Std Err of LS Mean = 991.966 
 
Least square means for [iron] :  
Group  Mean  
100.000 30767.167  
10.000 11882.667  
1.000  2548.333  
0.000  9.000  
Std Err of LS Mean = 1402.852 
 
Least square means for HMG 1.0mcM x [iron] :  
Group   Mean  
0.000 x 100.000 38220.333  
0.000 x 10.000 12564.000  
0.000 x 1.000 3803.667  
0.000 x 0.000 12.000  
1.000 x 100.000 23314.000  
1.000 x 10.000 11201.333  
1.000 x 1.000 1293.000  
1.000 x 0.000 6.000  
Std Err of LS Mean = 1983.932 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparisons for factor: HMG 1.0mcM 
Comparison Diff of Means  p q  P  P<0.050  
0.000 vs. 1.000 4696.417 2 4.734  0.004  Yes  
 
 
Comparisons for factor: [iron] 
Comparison Diff of Means  p q  P  P<0.050  
100.000 vs. 0.000 30758.167 4 21.925 <0.001 Yes  
100.000 vs. 1.000 28218.833 4 20.115 <0.001 Yes  
100.000 vs. 10.000 18884.500 4 13.462 <0.001 Yes  
10.000 vs. 0.000 11873.667 4 8.464  <0.001 Yes  
10.000 vs. 1.000 9334.333 4 6.654  0.001  Yes  
1.000 vs. 0.000 2539.333 4 1.810  0.588  No  
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Comparisons for factor: [iron] within 0 
Comparison Diff of Means  p q  P  P<0.05  
100.000 vs. 0.000 38208.333 4 19.259 <0.001 Yes  
100.000 vs. 1.000 34416.667 4 17.348 <0.001 Yes  
100.000 vs. 10.000 25656.333 4 12.932 <0.001 Yes  
10.000 vs. 0.000 12552.000 4 6.327  0.002  Yes  
10.000 vs. 1.000 8760.333 4 4.416  0.030  Yes  
1.000 vs. 0.000 3791.667 4 1.911  0.546  No  
 
 
Comparisons for factor: [iron] within 1 
Comparison Diff of Means  p q  P  P<0.05  
100.000 vs. 0.000 23308.000 4 11.748 <0.001 Yes  
100.000 vs. 1.000 22021.000 4 11.100 <0.001 Yes  
100.000 vs. 10.000 12112.667 4 6.105  0.003  Yes  
10.000 vs. 0.000 11195.333 4 5.643  0.005  Yes  
10.000 vs. 1.000 9908.333 4 4.994  0.013  Yes  
1.000 vs. 0.000 1287.000 4 0.649  0.967  No  
 
 
Comparisons for factor: HMG 1.0mcM within 100 
Comparison Diff of Means  p q  P  P<0.05  
0.000 vs. 1.000 14906.333 2 7.514  <0.001 Yes  
 
 
Comparisons for factor: HMG 1.0mcM within 10 
Comparison Diff of Means  p q  P  P<0.05  
0.000 vs. 1.000 1362.667 2 0.687  0.634  No  
 
 
Comparisons for factor: HMG 1.0mcM within 1 
Comparison Diff of Means  p q  P  P<0.05  
0.000 vs. 1.000 2510.667 2 1.266  0.384  No  
 
 
Comparisons for factor: HMG 1.0mcM within 0 
Comparison Diff of Means  p q  P  P<0.05  
0.000 vs. 1.000 6.000  2 0.00302 0.998  No  
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A16. Effect of HMG CoA Reductase Inhibition (Mevinolin) on 
Macrophage Uptake of Iron Oxide 
 
b. Mevinolin (17.5 µM) 
 
Two Way Analysis of Variance  
 
Source of 
Variation 
 DF   SS   MS    F    P  
HMG 1 283064622.042 283064622.042 26.913 <0.001 
[iron2] 3 2449715493.458 816571831.153 77.637 <0.001 
HMG x 
[iron2] 
3 496210450.792 165403483.597 15.726 <0.001 
Residual 16 168285499.333 10517843.708   
Total 23 3397276065.625 147707655.027   
    
The difference in the mean values among the different levels of HMG is greater 
than would be expected by chance after allowing for effects of differences in 
[iron2].  There is a statistically significant difference (P = <0.001).  To isolate 
which group(s) differ from the others use a multiple comparison procedure. 
 
The difference in the mean values among the different levels of [iron2] is greater 
than would be expected by chance after allowing for effects of differences in 
HMG.  There is a statistically significant difference (P = <0.001).  To isolate which 
group(s) differ from the others use a multiple comparison procedure. 
 
The effect of different levels of HMG depends on what level of [iron2] is present.  
There is a statistically significant interaction between HMG and [iron2].  (P = 
<0.001) 
 
Power of performed test with alpha = 0.0500:  for HMG : 0.999 
Power of performed test with alpha = 0.0500:  for [iron2] : 1.000 
Power of performed test with alpha = 0.0500:  for HMG x [iron2] : 1.000 
 
Least square means for HMG :  
Group  Mean  
0.000  10385.917  
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1.000  3517.333  
Std Err of LS Mean = 936.209 
 
Least square means for [iron2] :  
Group  Mean  
100.000 24288.000  
10.000 3416.167  
1.000  95.333  
0.000  7.000  
Std Err of LS Mean = 1323.999 
 
Least square means for HMG x [iron2] :  
Group   Mean  
0.000 x 100.000 35391.000  
0.000 x 10.000 5985.000  
0.000 x 1.000 155.667  
0.000 x 0.000 12.000  
1.000 x 100.000 13185.000  
1.000 x 10.000 847.333  
1.000 x 1.000 35.000  
1.000 x 0.000 2.000  
Std Err of LS Mean = 1872.418 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparisons for factor: HMG 
Comparison Diff of Means  p q  P  P<0.050  
0.000 vs. 1.000 6868.583 2 7.337  <0.001 Yes  
 
 
Comparisons for factor: [iron2] 
Comparison Diff of Means  p q  P  P<0.050  
100.000 vs. 0.000 24281.000 4 18.339 <0.001 Yes  
100.000 vs. 1.000 24192.667 4 18.272 <0.001 Yes  
100.000 vs. 10.000 20871.833 4 15.764 <0.001 Yes  
10.000 vs. 0.000 3409.167 4 2.575  0.300  No  
10.000 vs. 1.000 3320.833 4 2.508  0.321  Do Not Test  
1.000 vs. 0.000 88.333 4 0.0667 1.000  Do Not Test  
 
 
Comparisons for factor: [iron2] within 0 
Comparison Diff of Means  p q  P  P<0.05  
100.000 vs. 0.000 35379.000 4 18.895 <0.001 Yes  
100.000 vs. 1.000 35235.333 4 18.818 <0.001 Yes  
100.000 vs. 10.000 29406.000 4 15.705 <0.001 Yes  
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10.000 vs. 0.000 5973.000 4 3.190  0.151  No  
10.000 vs. 1.000 5829.333 4 3.113  0.165  Do Not Test  
1.000 vs. 0.000 143.667 4 0.0767 1.000  Do Not Test  
 
 
Comparisons for factor: [iron2] within 1 
Comparison Diff of Means  p q  P  P<0.05  
100.000 vs. 0.000 13183.000 4 7.041  <0.001 Yes  
100.000 vs. 1.000 13150.000 4 7.023  <0.001 Yes  
100.000 vs. 10.000 12337.667 4 6.589  0.001  Yes  
10.000 vs. 0.000 845.333 4 0.451  0.988  No  
10.000 vs. 1.000 812.333 4 0.434  0.990  Do Not Test  
1.000 vs. 0.000 33.000 4 0.0176 1.000  Do Not Test  
 
 
Comparisons for factor: HMG within 100 
Comparison Diff of Means  p q  P  P<0.05  
0.000 vs. 1.000 22206.000 2 11.860 <0.001 Yes  
 
 
Comparisons for factor: HMG within 10 
Comparison Diff of Means  p q  P  P<0.05  
0.000 vs. 1.000 5137.667 2 2.744  0.070  No  
 
 
Comparisons for factor: HMG within 1 
Comparison Diff of Means  p q  P  P<0.05 
0.000 vs. 1.000 120.667 2 0.0644 0.964  No  
 
Comparisons for factor: HMG within 0 
Comparison Diff of Means  p q  P  P<0.05  
0.000 vs. 1.000 10.000 2 0.00534 0.997  No 
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A17. Effect of HMG CoA Reductase Inhibition (Mevinolin) on 
Macrophage Uptake of Iron Oxide 
 
c. Mevinolin (17.5 µM) Data corrected for cell density 
 
Two Way Analysis of Variance  
Source of 
Variation 
 DF   SS   MS    F    P  
HMG 1 118368107.011 118368107.011 6.623 0.020 
[iron2] 3 3471907563.896 1157302521.299 64.753 <0.001 
HMG x 
[iron2] 
3 170484041.790 56828013.930 3.180 0.053 
Residual 16 285963005.284 17872687.830   
Total 23 4046722717.981 175944465.999   
 
 
The difference in the mean values among the different levels of HMG is 
greater than would be expected by chance after allowing for effects of 
differences in [iron2].  There is a statistically significant difference (P = 0.020).  
To isolate which group(s) differ from the others use a multiple comparison 
procedure. 
 
The difference in the mean values among the different levels of [iron2] is 
greater than would be expected by chance after allowing for effects of 
differences in HMG.  There is a statistically significant difference (P = <0.001).  
To isolate which group(s) differ from the others use a multiple comparison 
procedure. 
 
The effect of different levels of HMG does not depend on what level of [iron2] 
is present.  There is not a statistically significant interaction between HMG 
and [iron2].  (P = 0.053) 
 
Power of performed test with alpha = 0.0500:  for HMG : 0.604 
Power of performed test with alpha = 0.0500:  for [iron2] : 1.000 
Power of performed test with alpha = 0.0500:  for HMG x [iron2] : 0.446 
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Least square means for HMG :  
Group Mean  
0.000 10385.917  
1.000 5944.293  
Std Err of LS Mean = 1220.406 
 
Least square means for [iron2] :  
Group Mean  
100.000 28836.825  
10.000 3708.497  
0.000 7.690  
1.000 107.408  
Std Err of LS Mean = 1725.915 
 
Least square means for HMG x [iron2] :  
Group   Mean  
0.000 x 100.000  35391.000  
0.000 x 10.000  5985.000  
0.000 x 0.000  12.000  
0.000 x 1.000  155.667  
1.000 x 100.000  22282.650  
1.000 x 10.000  1431.993  
1.000 x 0.000  3.380  
1.000 x 1.000  59.150 
1.000 x 0.000  3.380  
1.000 x 1.000  59.150  
Std Err of LS Mean = 2440.812 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparisons for factor: HMG 17.5 M (corrected for cell density) 
Comparison Diff of Means  p q P   P<0.050  
0.000 vs. 1.000 4441.623  2 3.639 0.021   Yes  
 
 
Comparisons for factor: [iron2] 
Comparison Diff of Means  p q  P     P<0.050  
100.000 vs. 0.000 28829.135 4 16.704 <0.001 Yes  
100.000 vs. 1.000 28729.417 4 16.646 <0.001 Yes  
100.000 vs. 10.000 25128.328 4 14.559 <0.001 Yes  
10.000 vs. 0.000 3700.807  4 2.144  0.451  No  
10.000 vs. 1.000 3601.088  4 2.086  0.474 Do Not Test  
1.000 vs. 0.000 99.718  4 0.0578 1.000 Do Not Test  
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Comparisons for factor: [iron2] within 0 
Comparison Diff of Means  p    q      P  P<0.05  
100.000 vs. 0.000 35379.000  4 14.495  <0.001  Yes  
100.000 vs. 1.000 35235.333  4 14.436  <0.001  Yes  
100.000 vs. 10.000 29406.000  4 12.048  <0.001  Yes  
10.000 vs. 0.000 5973.000  4 2.447  0.341  No  
10.000 vs. 1.000 5829.333  4 2.388  0.361    Do Not Test  
1.000 vs. 0.000 143.667  4 0.0589  1.000    Do Not Test  
 
 
Comparisons for factor: [iron2] within 1 
Comparison Diff of Means  p q  P        P<0.05  
100.000 vs. 0.000 22279.270 4 9.128  <0.001 Yes  
100.000 vs. 1.000 22223.500 4 9.105  <0.001 Yes  
100.000 vs. 10.000 20850.657 4 8.543  <0.001 Yes  
10.000 vs. 0.000 1428.613  4 0.585  0.975             No  
10.000 vs. 1.000 1372.843  4 0.562  0.978   Do Not Test  
1.000 vs. 0.000 55.770  4 0.0228 1.000   Do Not Test  
  
 
Comparisons for factor: HMG within 100 
Comparison Diff of Means  p q  P      P<0.05  
0.000 vs. 1.000 13108.350  2 5.370  0.002        Yes  
 
 
Comparisons for factor: HMG within 10 
Comparison Diff of Means  p q  P      P<0.05  
0.000 vs. 1.000 4553.007  2 1.865  0.206          No  
 
 
Comparisons for factor: HMG within 0 
Comparison Diff of Means   p q P    P<0.05  
0.000 vs. 1.000 8.620   2 0.00353 0.998      No  
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